
    
<!DOCTYPE html>




<html lang="en" >
<head >
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <!-- Mobile properties -->
    <meta name="HandheldFriendly" content="True">
    <meta name="MobileOptimized" content="320">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">

  
    <!-- Stylesheets -->
    <link rel="stylesheet" href="/pmc/static/CACHE/css/output.cc84172e9e16.css" type="text/css">
  
  <link rel="stylesheet" href="/pmc/static/CACHE/css/output.b634933a977d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.913c7dcab8ff.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.3766d7ad0d2d.css" type="text/css"><link rel="stylesheet" href="/pmc/static/CACHE/css/output.e3c3c2c84eb3.css" type="text/css">

  
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.7.0/css/font-awesome.min.css"/>
  
<link type="text/css" href="/pmc/static/bundles/base/base.a2ef7ca69e4b20dff539.css" rel="stylesheet" />


    <link rel="stylesheet" href="/corehtml/pmc/css/fonts/stix/stixfonts.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.18/pmcrefs1.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/pmc2020_1.1/ncbi_web.min.css?_=a" type="text/css" /><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-journal.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style>

    <link type="text/css" href="/pmc/static/bundles/article/article.3c5d12ff2e4beea20136.css" rel="stylesheet" />
    <link type="text/css" href="/pmc/static/django_pmc_cite_box/lib/cite-box.css" rel="stylesheet" />


    <title>HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts - PMC</title>

  
  <!-- Favicons -->
  <link rel="shortcut icon" type="image/ico" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico" />
  <link rel="icon" type="image/png" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.png" />

  <!-- 192x192, as recommended for Android
  http://updates.html5rocks.com/2014/11/Support-for-theme-color-in-Chrome-39-for-Android
  -->
  <link rel="icon" type="image/png" sizes="192x192" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-192.png" />

  <!-- 57x57 (precomposed) for iPhone 3GS, pre-2011 iPod Touch and older Android devices -->
  <link rel="apple-touch-icon-precomposed" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-57.png">
  <!-- 72x72 (precomposed) for 1st generation iPad, iPad 2 and iPad mini -->
  <link rel="apple-touch-icon-precomposed" sizes="72x72" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-72.png">
  <!-- 114x114 (precomposed) for iPhone 4, 4S, 5 and post-2011 iPod Touch -->
  <link rel="apple-touch-icon-precomposed" sizes="114x114" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-114.png">
  <!-- 144x144 (precomposed) for iPad 3rd and 4th generation -->
  <link rel="apple-touch-icon-precomposed" sizes="144x144" href="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon-144.png">



    
        <!-- Logging params: Pinger defaults -->

<meta name="ncbi_app" content="pmc-frontend" />

<meta name="ncbi_db" content="pmc" />

<meta name="ncbi_phid" content="322C300B24F39205000031858992D83B.1.m_2" />


        <!-- Logging params: Pinger custom -->

<meta name="ncbi_pdid" content="article" />

<meta name="ncbi_op" content="retrieved" />

<meta name="ncbi_app_version" content="0.0" />

<meta name="ncbi_domain" content="plosone" />

<meta name="ncbi_type" content="fulltext" />

<meta name="ncbi_pcid" content="/articles/PMC3064677/" />


    


    <script>
        
            var ncbiBaseUrl = "https://www.ncbi.nlm.nih.gov";
        
        var useOfficialGovtHeader = true;
    </script>


    <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064677/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="PLoS ONE" /><meta name="citation_title" content="HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts" /><meta name="citation_author" content="Tapan K. Nayak" /><meta name="citation_author_institution" content="Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America" /><meta name="citation_author" content="Kayhan Garmestani" /><meta name="citation_author_institution" content="Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America" /><meta name="citation_author" content="Diane E. Milenic" /><meta name="citation_author_institution" content="Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America" /><meta name="citation_author" content="Kwamena E. Baidoo" /><meta name="citation_author_institution" content="Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America" /><meta name="citation_author" content="Martin W. Brechbiel" /><meta name="citation_author_institution" content="Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America" /><meta name="citation_publication_date" content="2011" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="6" /><meta name="citation_doi" content="10.1371/journal.pone.0018198" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3064677/?report=abstract" /><meta name="citation_fulltext_html_url" content="/pmc/articles/PMC3064677/" /><meta name="citation_pmid" content="21464917" /><meta name="DC.Title" content="HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="PLOS" /><meta name="DC.Contributor" content="Tapan K. Nayak" /><meta name="DC.Contributor" content="Kayhan Garmestani" /><meta name="DC.Contributor" content="Diane E. Milenic" /><meta name="DC.Contributor" content="Kwamena E. Baidoo" /><meta name="DC.Contributor" content="Martin W. Brechbiel" /><meta name="DC.Date" content="2011" /><meta name="DC.Identifier" content="10.1371/journal.pone.0018198" /><meta name="DC.Language" content="en" /><meta property="og:title" content="HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts" /><meta property="og:type" content="article" /><meta property="og:description" content="Malignant mesothelioma (MM), a rare form of cancer is often associated with previous exposure to fibrous minerals, such as asbestos. Asbestos exposure increases HER1-activity and expression in pre-clinical models. Additionally, HER1 over-expression is ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064677/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0" /><meta name="twitter:card" content="summary_large_image" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" />


</head>
<body >

   
    
        <button
          class="back-to-top back-to-top--bottom"
          data-ga-category="pagination"
          data-ga-action="back_to_top">
          Back to Top
        </button>
    

    <a class="usa-skipnav" href="#main-content">Skip to main content</a>
    <!-- ========== BEGIN HEADER ========== -->
<section class="usa-banner" style="display: none;">
  <div class="usa-accordion">
    <header class="usa-banner-header">
      <div class="usa-grid usa-banner-inner">
        <img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
        <p>An official website of the United States government</p>
        <button
          class="usa-accordion-button usa-banner-button"
          aria-expanded="false"
          aria-controls="gov-banner-top"
        >
          <span class="usa-banner-button-text">Here's how you know</span>
        </button>
      </div>
    </header>
    <div
      class="usa-banner-content usa-grid usa-accordion-content"
      id="gov-banner-top"
    >
      <div class="usa-banner-guidance-gov usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg"
          alt="Dot gov"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The .gov means it’s official.</strong>
            <br />
            Federal government websites often end in .gov or .mil. Before
            sharing sensitive information, make sure you’re on a federal
            government site.
          </p>
        </div>
      </div>
      <div class="usa-banner-guidance-ssl usa-width-one-half">
        <img
          class="usa-banner-icon usa-media_block-img"
          src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg"
          alt="Https"
        />
        <div class="usa-media_block-body">
          <p>
            <strong>The site is secure.</strong>
            <br />
            The <strong>https://</strong> ensures that you are connecting to the
            official website and that any information you provide is encrypted
            and transmitted securely.
          </p>
        </div>
      </div>
    </div>
  </div>
</section>
<div class="usa-overlay"></div>
<header class="ncbi-header" role="banner" data-section="Header">

	<div class="usa-grid">
		<div class="usa-width-one-whole">

            <div class="ncbi-header__logo">
                <a href="https://www.ncbi.nlm.nih.gov/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
                  <img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
                </a>
            </div>

			<div class="ncbi-header__account">
				<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
				<button id="account_info" class="header-button" style="display:none"
						aria-controls="account_popup">
					<span class="fa fa-user" aria-hidden="true"></span>
					<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
					<span class="sr-only">Show account info</span>
				</button>
			</div>

			<div class="ncbi-popup-anchor">
				<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
					<div class="ncbi-popup-head">
						<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu"><span class="fa fa-times"></span><span class="usa-sr-only">Close</span></button>
						<h4>Account</h4>
					</div>
					<div class="account-user-info">
						Logged in as:<br/>
						<b><span class="username" id="uname_long">username</span></b>
					</div>
					<div class="account-links">
						<ul class="usa-unstyled-list">
							<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
							<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
							<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
							<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
						</ul>
					</div>
				</div>
			</div>

		</div>
	</div>
</header>
<div role="navigation" aria-label="access keys">
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
</div>
<section data-section="Alerts">
	<div class="ncbi-alerts-placeholder"></div>
</section>
<!-- ========== END HEADER ========== -->

    
    


    
        

<section class="pmc-alerts">
    
    <div role="alert" class="pmc-alert pmc-alert--info" role="region" aria-label="Alert" aria-hidden="false"  data-key="pmc-alert-welcome">
        <div class="pmc-alert__body pmc-alert--ncbi-icon">
            <div class="pmc-alert__content">
                <p>
                    <strong>
                        Preview improvements coming to the PMC website in October 2024.
                        <a href="https://ncbiinsights.ncbi.nlm.nih.gov/2024/03/14/preview-pmc-improvements/" data-ga-category="cloud_beta_banner" data-ga-label="learn_more" data-ga-action="on_pmc2020">Learn More</a> or
                        <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3064677/" data-ga-category="cloud_beta_banner" data-ga-action="on_pmc2020" data-ga-label="go_to_cloud">Try it out now</a>.
                    </strong>
                </p>
            </div>
        </div>
    </div>
    
</section>
    

    
    
        
        <header class="pmc-header usa-header-extended" role="banner">
    <div class="pmc-header__bar">
        <div class="pmc-header__control usa-accordion">
            
                <button class="usa-menu-btn pmc-header--button pmc-header--left">
                    <i class="fa fa-ellipsis-v" aria-hidden="true"></i>
                </button>
            

            <div class="usa-logo pmc-header__logo pmc-header--stretch
                
               " id="extended-mega-logo">
                <div class="usa-logo-text">
                    <a href="/pmc/" title="Home" aria-label="Home" ></a>
                </div>
            </div>
            <button class="usa-accordion-button pmc-header--right pmc-header--button pmc-header__search--control pmc-header--right" aria-expanded="false" aria-controls="a1">
                <i class="fa fa-search" aria-hidden="true"></i>
                <i class="fa fa-times" aria-hidden="true"></i>
            </button>
        </div>
        <div class="pmc-header__search usa-accordion-content" id="a1">
            <div role="search"  class="pmc-header--stretch"  >
    <form class="usa-search " autocomplete="off">
        <div>
              <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
              <span class="clearable">
                <input
                  required="required"
                  autocomplete-url="/pmc/autocomplete/pmc/"
                  placeholder="Search PMC Full-Text Archive"
                  id="pmc-search" type="search" name="term"/>
                  <i class="clear-btn" ></i>
              </span>
              <button type="submit" formaction="/pmc/">
                <span class="usa-search-submit-text">Search in PMC</span>
              </button>
        </div>
    </form>
</div>


            <ul class="usa-unstyled-list usa-nav-secondary-links pmc-header--offset-two">
                    <li>
                        <a href="https://www.ncbi.nlm.nih.gov/pmc/advanced" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        <a  href="/pmc/about/userguide/" data-ga-action="featured_link"
                        data-ga-label="user guide">
                            User Guide
                        </a>
                    </li>
            </ul>
        </div>
    </div>
     <nav role="navigation" class="usa-nav ">
        <button class="usa-nav-close">
            <i class="fa fa-times" aria-hidden="true"></i>
        </button>
        <div class="usa-breadcrumb usa-breadcrumb--wrap usa-breadcrumb--hack">
             
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22PLoS%20One%22[journal]" class="navlink">PLoS One</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC3064677
                </li>
            
    </ul>
 

        </div>
        
        
            <div class="pmc-sidebar pmc-sidebar-hack">
                

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC3064677/pdf/pone.0018198.pdf" class="int-view">PDF (1.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/3064677/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/3064677/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="3064677" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="kKxztmzvrziR0as7FBAJPdB0Gt4Kg5G4p6vVAryEaCouXy5CAWN8Se6IHA7H9qmn">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-header "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-header ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-header "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-header ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F&amp;text=HER1-Targeted%2086Y-Panitumumab%20Possesses%20Superior%20Targeting%20Characteristics%20than%2086Y-Cetuximab%20for%20PET%20Imaging%20of%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064677/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/21464917/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-header" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/21464917/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-header"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-header"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/3064677/" class="usa-accordion-content" id="links-accordion-header" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>
            </div>
        

    </nav>

</header>

    
    

    <div class="usa-overlay"></div>
    
<main id="main-content" class="usa-grid usa-layout-docs pmc-main">
    <article class="usa-width-three-fourths usa-layout-docs-main_content pmc-article">
        <section class="usa-breadcrumb usa-breadcrumb--wrap">
         
    <ul class="usa-breadcrumb__list">
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/journals/" class="navlink">Journal List</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                    >
                    <a href="/pmc/?term=%22PLoS%20One%22[journal]" class="navlink">PLoS One</a>
                </li>
            
                <li class="usa-breadcrumb__list-item"
                     aria-current="page" >
                    PMC3064677
                </li>
            
    </ul>
 

        </section>
        
  <div class="pmc-article__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/pmc/about/disclaimer/">PMC Disclaimer</a>
    |
    <a data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/pmc/about/copyright/">
        PMC Copyright Notice
    </a>
</div>

        <section class="pmc-page-banner" role="banner">
            
                
                    <div><img src="/corehtml/pmc/pmcgifs/logo-plosone.png" alt="Logo of plosone" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher's site" title="Link to Publisher's site" shape="default" coords="0,0,499,74" href="https://journals.plos.org/plosone/" target="_blank" rel="noopener noreferrer" ref="reftype=publisher&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" /></map></div> 
                
            
        </section>
        <section  role="document">
            
                <div id="mc" class=" article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden,.nomenu'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-flexbox"><div class="fm-citation"><div class="citation-default"><div class="part1"><span id="pmcmata">PLoS One.</span> 2011; 6(3): e18198. </div><div class="part2"><span class="fm-vol-iss-date">Published online 2011 Mar 25. </span>  <span class="doi"><span>doi: </span><a href="//doi.org/10.1371%2Fjournal.pone.0018198" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.pone.0018198</a></span></div></div></div><div class="fm-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3064677</span></div><div class="fm-citation-pmid">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21464917">21464917</a></div></div></div><h1 class="content-title">HER1-Targeted <sup>86</sup>Y-Panitumumab Possesses Superior Targeting Characteristics than <sup>86</sup>Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nayak%20TK%5BAuthor%5D" class="affpopup" co-rid="_co_idm140503911152096" co-class="co-affbox">Tapan K. Nayak</a>,<sup></sup><sup>
&#x0002a;
</sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garmestani%20K%5BAuthor%5D" class="affpopup" co-rid="_co_idm140503910988496" co-class="co-affbox">Kayhan Garmestani</a>,<sup></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Milenic%20DE%5BAuthor%5D" class="affpopup" co-rid="_co_idm140503902191664" co-class="co-affbox">Diane E. Milenic</a>,<sup></sup> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baidoo%20KE%5BAuthor%5D" class="affpopup" co-rid="_co_idm140503944308768" co-class="co-affbox">Kwamena E. Baidoo</a>,<sup></sup> and  <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Brechbiel%20MW%5BAuthor%5D" class="affpopup" co-rid="_co_idm140503944306912" co-class="co-affbox">Martin W. Brechbiel</a><sup></sup><sup>
&#x0002a;
</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140503911152096"><h3 class="no_margin">Tapan K. Nayak</h3><p>
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Nayak%20TK%5BAuthor%5D">Tapan K. Nayak</a></div></div><div id="_co_idm140503910988496"><h3 class="no_margin">Kayhan Garmestani</h3><p>
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Garmestani%20K%5BAuthor%5D">Kayhan Garmestani</a></div></div><div id="_co_idm140503902191664"><h3 class="no_margin">Diane E. Milenic</h3><p>
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Milenic%20DE%5BAuthor%5D">Diane E. Milenic</a></div></div><div id="_co_idm140503944308768"><h3 class="no_margin">Kwamena E. Baidoo</h3><p>
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baidoo%20KE%5BAuthor%5D">Kwamena E. Baidoo</a></div></div><div id="_co_idm140503944306912"><h3 class="no_margin">Martin W. Brechbiel</h3><p>
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</p><div>Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=Brechbiel%20MW%5BAuthor%5D">Martin W. Brechbiel</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Andrew Yeudall, <span class="fm-role">Editor</span><sup></sup></div><div class="half_rhythm"><div class="togglers fm-copyright-license"><a href="#" class="pmctoggle" rid="idm140503903374672_ai idm140503911152224_ai idm140503906678272_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140503903374672_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140503903374672_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/" style="margin-left: 1em">PMC Disclaimer</a></div><div class="fm-authors-info hide half_rhythm" id="idm140503903374672_ai" style="display:none"><div class="fm-affl" id="aff1">
Radioimmune &#x00026; Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, United States of America
</div><div class="fm-affl" id="edit1">Virginia Commonwealth University, United States of America</div><div id="cor1">&#x0002a; E-mail: <a href="mailto:dev@null" data-email="moc.liamg@nnapat" class="oemail">moc.liamg@nnapat</a> (TKN); <a href="mailto:dev@null" data-email="vog.hin.liam@bwnitram" class="oemail">vog.hin.liam@bwnitram</a> (MWB)</div><div><p class="p p-first-last">Conceived and designed the experiments: TKN DEM MWB. Performed the experiments: TKN KG KEB DEM. Analyzed the data: TKN DEM. Contributed reagents/materials/analysis tools: TKN DEM KG KEB. Wrote the paper: TKN.</p></div></div><div class="fm-article-notes hide half_rhythm" id="idm140503903374672_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Oct 28; Accepted 2011 Feb 28.</div></div><div class="permissions half_rhythm hide" id="idm140503903374672_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm hidden" role="complementary" aria-label="Related or updated information about this article."></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2 class="nomenu">Associated Data</h2><dl data-count="1" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Table S1: </strong>Relative <em>in vitro</em> expression of HER1 in human mesothelioma cells determined by FACS based assay. MFI &#x0200a;=&#x0200a; mean fluorescence intensity.<p>(DOC)</p></div><div><a href="/pmc/articles/PMC3064677/bin/pone.0018198.s001.doc" data-ga-action="click_feat_suppl">pone.0018198.s001.doc</a><span style="color:gray"> (36K)</span></div><div class="small guid">GUID: 9BBB7188-3589-4398-8041-7AA6C86247E1</div></div></dd></dl></div><div id="abstract-a.l.b.r" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="abstract-a.l.b.rtitle">Abstract</h2><!--article-meta--><div><div id="sec-a.l.b.r.a" class="sec sec-first"><p class="p p-first-last">Malignant mesothelioma (MM), a rare form of cancer is often associated with previous exposure to fibrous minerals, such as asbestos. Asbestos exposure increases HER1-activity and expression in pre-clinical models. Additionally, HER1 over-expression is observed in the majority of MM cases. In this study, the utility of HER1-targeted chimeric IgG<sub>1</sub>, cetuximab, and a human IgG<sub>2</sub>, panitumumab, radiolabeled with <sup>86</sup>Y, were evaluated for PET imaging to detect MM non-invasively <em>in vivo</em>, and to select an antibody candidate for radioimmunotherapy (RIT).</p></div><div id="sec-a.l.b.r.b" class="sec"><h3 id="sec-a.l.b.r.btitle">Methods</h3><p class="p p-first-last">Radioimmunoconjugates (RICs) of cetuximab and panitumumab were prepared by conjugation with CHX-A&#x02019;&#x02019;-DTPA followed by radiolabeling with <sup>86</sup>Y. The HER1 expression of NCI-H226, NCI-H2052, NCI-H2452 and MSTO-211H human mesothelioma cells was characterized by flow cytometry. <em>In vivo</em> biodistribution, pharmacokinetic analysis, and PET imaging were performed in tumor bearing athymic mice.</p></div><div id="sec-a.l.b.r.c" class="sec"><h3 id="sec-a.l.b.r.ctitle">Results</h3><p class="p p-first-last">
<em>In vivo</em> studies demonstrated high HER1 tumor uptake of both RICs. Significant reduction in tumor uptake was observed in mice co-injected with excess mAb (0.1 mg), demonstrating that uptake in the tumor was receptor specific. Significant differences were observed in the <em>in vivo</em> characteristics of the RICs. The blood clearance T<sub>&#x000bd;</sub>&#x003b1; of <sup>86</sup>Y-cetuximab (0.9&#x02013;1.1 h) was faster than <sup>86</sup>Y-panitumumab (2.6&#x02013;3.1 h). Also, the tumor area under the curve (AUC) to liver AUC ratios of <sup>86</sup>Y-panitumumab were 1.5 to 2.5 times greater than <sup>86</sup>Y-cetuximab as observed by the differences in PET tumor to background ratios, which could be critical when imaging orthotopic tumors and concerns regarding radiation doses to normal organs such as the liver.</p></div><div id="sec-a.l.b.r.d" class="sec sec-last"><h3 id="sec-a.l.b.r.dtitle">Conclusion</h3><p class="p p-first-last">This study demonstrates the more favorable HER1-targeting characteristics of <sup>86</sup>Y-panitumumab than <sup>86</sup>Y-cetuximab for non-invasive assessment of the HER1 status of MM by PET imaging. Due to lower liver uptake, panitumumab based immunoconjugates may fare better in therapy than corresponding cetuximab based immunoconjugates.</p></div></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p class="p p-first">Asbestos-related deaths have increased 400 percent in the past 20 years and the number of cases continues to increase despite awareness of asbestos-related hazards <a href="#pone.0018198-Yang1" rid="pone.0018198-Yang1" class=" bibr popnode">[1]</a>, <a href="#pone.0018198-Kamp1" rid="pone.0018198-Kamp1" class=" bibr popnode">[2]</a>. Asbestos is a human mutagen and carcinogen, responsible for many pulmonary diseases including asbestosis, bronchogenic carcinoma, and malignant mesothelioma <a href="#pone.0018198-Kamp1" rid="pone.0018198-Kamp1" class=" bibr popnode">[2]</a>. Malignant mesothelioma (MM) is a rare form of an aggressive and often treatment-resistant cancer <a href="#pone.0018198-Robinson1" rid="pone.0018198-Robinson1" class=" bibr popnode">[3]</a>. Occupational exposure to asbestos is implicated in 70&#x02013;80&#x00025; of all MM. After initial diagnosis, MM has a median survival of 10&#x02013;18 months <a href="#pone.0018198-Robinson1" rid="pone.0018198-Robinson1" class=" bibr popnode">[3]</a>, <a href="#pone.0018198-Vogelzang1" rid="pone.0018198-Vogelzang1" class=" bibr popnode">[4]</a>. Conventional therapies, such as surgery, radiotherapy, and chemotherapy, do not necessarily improve overall survival. On the other hand, tremendous advances have been made regarding understanding the molecular biology of MM.</p><p>Understanding the molecular biological features of asbestos-induced MM is of critical importance. MM cells arise from the pleura or the peritoneal cavity and produce numerous growth factors, including epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and transforming growth factor &#x003b2; (TGF-&#x003b2;) <a href="#pone.0018198-Robinson1" rid="pone.0018198-Robinson1" class=" bibr popnode">[3]</a>, <a href="#pone.0018198-Robinson2" rid="pone.0018198-Robinson2" class=" bibr popnode">[5]</a>, <a href="#pone.0018198-Lee1" rid="pone.0018198-Lee1" class=" bibr popnode">[6]</a>. EGF is a potent mitogen for human mesothelial cells. In normal and pre-malignant animal cells of similar type, exposure to asbestos leads to autophosphorylation, increased expression of the cell surface EGF receptor (HER1) that then appears to initiate cell signaling cascades important in asbestos-induced mitogenesis and carcinogenesis <a href="#pone.0018198-Pache1" rid="pone.0018198-Pache1" class=" bibr popnode">[7]</a>, <a href="#pone.0018198-Zanella1" rid="pone.0018198-Zanella1" class=" bibr popnode">[8]</a>, <a href="#pone.0018198-Faux1" rid="pone.0018198-Faux1" class=" bibr popnode">[9]</a>.</p><p>Recent clinical studies have also shown over-expression of HER1 in MM <a href="#pone.0018198-Gaafar1" rid="pone.0018198-Gaafar1" class=" bibr popnode">[10]</a>, <a href="#pone.0018198-Kothmaier1" rid="pone.0018198-Kothmaier1" class=" bibr popnode">[11]</a>, <a href="#pone.0018198-Edwards1" rid="pone.0018198-Edwards1" class=" bibr popnode">[12]</a>, <a href="#pone.0018198-Okuda1" rid="pone.0018198-Okuda1" class=" bibr popnode">[13]</a>. In an immunohistochemical (IHC) and molecular study with clinico-pathological correlations, a statistically significant correlation was observed between the expression of HER1 by IHC and corresponding mRNA levels. Secondly, HER1 mRNA levels were higher in tumor specimens than non-neoplastic pleura samples <a href="#pone.0018198-Destro1" rid="pone.0018198-Destro1" class=" bibr popnode">[14]</a>. In another study comprising 71 patients, high HER1 expression was detected in 74.6&#x00025; of the cases; 52.1&#x00025; cases were positive for HER1 gene amplification and 45&#x00025; of the cases had elevated serum HER1 <a href="#pone.0018198-Gaafar1" rid="pone.0018198-Gaafar1" class=" bibr popnode">[10]</a>. In that same study, elevated serum and tissue HER1 was significantly associated with advanced disease stage, suggesting an important role of EGFR over-expression in mesothelioma <a href="#pone.0018198-Gaafar1" rid="pone.0018198-Gaafar1" class=" bibr popnode">[10]</a>,<a href="#pone.0018198-Kothmaier1" rid="pone.0018198-Kothmaier1" class=" bibr popnode">[11]</a>,<a href="#pone.0018198-Edwards1" rid="pone.0018198-Edwards1" class=" bibr popnode">[12]</a>,<a href="#pone.0018198-Okuda1" rid="pone.0018198-Okuda1" class=" bibr popnode">[13]</a>.</p><p>Based on the findings that HER1 is over-expressed in MM, HER1-tyrosine kinase inhibitors (TKIs) such as gefinitib and erlotinib were investigated for therapy of MM patients <a href="#pone.0018198-Garland1" rid="pone.0018198-Garland1" class=" bibr popnode">[15]</a>, <a href="#pone.0018198-Govindan1" rid="pone.0018198-Govindan1" class=" bibr popnode">[16]</a>. In the study utilizing gefinitib, 97&#x00025; of the patients with MM were found to have presented with disease that over-expressed HER1, the gefitinib therapy, however, was ineffective and HER1 expression did not correlate with failure-free survival <a href="#pone.0018198-Govindan1" rid="pone.0018198-Govindan1" class=" bibr popnode">[16]</a>. Similarly, single agent erlotinib therapy was ineffective in MM, despite high expression of HER1. The authors speculated that the activation of the ERK and phosphatidylinositol 3-kinase/Akt downstream pathways as possible resistance mechanisms to erlotinib <a href="#pone.0018198-Garland1" rid="pone.0018198-Garland1" class=" bibr popnode">[15]</a>.</p><p>Since the majority of MMs over-express HER1, this target might prove suitable for molecular imaging and, ultimately, targeted radionuclide therapy of MM. Targeted radionuclide therapy and radioimmunotherapy (RIT) are at the forefront of molecular cancer treatment modalities that involve the use of cancer cell targeting radiopharmaceuticals, such as radiolabeled antibodies, which selectively target certain tumor cells <a href="#pone.0018198-Boswell1" rid="pone.0018198-Boswell1" class=" bibr popnode">[17]</a>, <a href="#pone.0018198-Sharkey1" rid="pone.0018198-Sharkey1" class=" bibr popnode">[18]</a>. <sup>90</sup>Y is one of the very promising radionuclides used for radioimmunotherapy of hematologic malignancies and solid tumors <a href="#pone.0018198-Zinzani1" rid="pone.0018198-Zinzani1" class=" bibr popnode">[19]</a>, <a href="#pone.0018198-Richman1" rid="pone.0018198-Richman1" class=" bibr popnode">[20]</a>, <a href="#pone.0018198-Wong1" rid="pone.0018198-Wong1" class=" bibr popnode">[21]</a> Such radionuclide therapy outcomes will be independent of mutations in HER1 or <em>KRAS</em> domains and therefore overcome the existing limitations of conventional HER1-targeted therapy. However, since <sup>90</sup>Y is a pure &#x000df;<sup>&#x02212;</sup>-emitter, its biodistribution cannot be readily imaged for patient-specific dosimetry which is essential for pre-therapeutic treatment planning and accurate absorbed dose estimation in individual patients to mitigate radiation risks. <sup>111</sup>In and <sup>89</sup>Zr were used as surrogate PET radionuclides for <sup>90</sup>Y, however disparities were observed in the biodistribution of these and <sup>90</sup>Y labeled antibodies <a href="#pone.0018198-Verel1" rid="pone.0018198-Verel1" class=" bibr popnode">[22]</a>, <a href="#pone.0018198-Lovqvist1" rid="pone.0018198-Lovqvist1" class=" bibr popnode">[23]</a>. In recent years, <sup>86</sup>Y has gained popularity as an attractive surrogate for studying <sup>90</sup>Y due to its half-life (14. 7 h) and positron emission which allows quantitative imaging over 2&#x02013;3 days <a href="#pone.0018198-Helisch1" rid="pone.0018198-Helisch1" class=" bibr popnode">[24]</a>. Since the chemical form is identical to <sup>90</sup>Y, <sup>86</sup>Y labeled antibodies have identical biodistribution to <sup>90</sup>Y labeled antibodies, and therefore should enable more accurate absorbed dose estimates for <sup>90</sup>Y <a href="#pone.0018198-Nayak1" rid="pone.0018198-Nayak1" class=" bibr popnode">[25]</a>. Based on the previous experiences with <sup>64</sup>Cu (half-life &#x0200a;=&#x0200a;12. 7 h) labeled antibodies in patients it is anticipated that between 0.18&#x02013;0.37 GBq of the injected <sup>86</sup>Y labeled antibody will result in useful quantitative images up to 2&#x02013;3 d after injection <a href="#pone.0018198-Philpott1" rid="pone.0018198-Philpott1" class=" bibr popnode">[26]</a>, <a href="#pone.0018198-Cutler1" rid="pone.0018198-Cutler1" class=" bibr popnode">[27]</a>. Therefore, in this study we sought to explore the utility of HER1-targeting <sup>86</sup>Y-labeled cetuximab and panitumumab for PET imaging of MM, to assess HER1 status, and as a means to select and screen subjects for HER1-targeted radioimmunotherapy (RIT) with radionuclides such as <sup>90</sup>Y for larger tumors or &#x003b1;-emitting radionuclides such as <sup>212</sup>Pb for micrometastatic disease <a href="#pone.0018198-Milenic1" rid="pone.0018198-Milenic1" class=" bibr popnode">[28]</a>, <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>, <a href="#pone.0018198-Nayak3" rid="pone.0018198-Nayak3" class=" bibr popnode">[30]</a>, <a href="#pone.0018198-Behr1" rid="pone.0018198-Behr1" class=" bibr popnode">[31]</a>.</p><p class="p p-last">In the present study, the <em>in vitro</em> characterization of four established MM cell lines for HER1 expression is described. Also detailed are the <em>in vivo</em> targeting characteristics of <sup>86</sup>Y-labeled panitumumab and cetuximab in three human MM tumor xenograft models in mice for potential use in risk stratification and quantitative non-invasive imaging of HER1, and assessment of mAb uptake in MM. In addition to the development of a potential PET imaging agent, another objective of the studies described herein was the selection of a preferred antibody candidate for future RIT studies.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Results</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">
<em>In vitro</em> evaluations</h3><div id="s2a1" class="sec sec-first"><p></p><h4 id="s2a1title" class="inline">Flow cytometric analysis </h4><p class="p p-first-last">Flow cytometric analysis revealed varied levels of HER1-expression for the mesothelioma cell lines evaluated (<a href="#pone.0018198.s001" rid="pone.0018198.s001" class=" supplementary-material">Table S1</a>). NCI-H226 had the highest mean fluorescence intensity (MFI), whereas NCI-H2452 had the lowest MFI (<a href="#pone.0018198.s001" rid="pone.0018198.s001" class=" supplementary-material">Table S1</a>). Panitumumab and cetuximab demonstrated comparable <em>in vitro</em> binding characteristics for each cell type, as evidenced by the percentage of cells stained with each of the mAb.</p></div><div id="s2a2" class="sec sec-last"><p></p><h4 id="s2a2title" class="inline">Radiochemistry </h4><p class="p p-first-last">The <sup>86</sup>Y labeled RICs were successfully prepared with radiochemical yields ranging from 60-75&#x00025;, specific activity exceeding 2 GBq/mg, and with acceptable <em>in vitro</em> receptor-specificity as previously described <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>, <a href="#pone.0018198-Nayak3" rid="pone.0018198-Nayak3" class=" bibr popnode">[30]</a>.</p></div></div><div id="s2b" class="sec sec-last"><h3 id="s2btitle">
<em>In vivo</em> evaluations</h3><div id="s2b1" class="sec sec-first"><p></p><h4 id="s2b1title" class="inline">Biodistribution studies </h4><p class="p p-first">In mice bearing the NCI-H226 tumor xenograft, significant decreases in the blood pool activity was observed over a 4 d time period for both RICs (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>). For <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab, the blood &#x00025; ID/g decreased from 12.06&#x000b1;1.28 at 1 d to 6.94&#x000b1;1.09&#x00025; ID/g at 4 d, a 43&#x00025; decrease. <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab showed an even greater decrease beginning with a blood &#x00025;ID/g of 11.70&#x000b1;1.44&#x00025; ID/g at 1 d and ending with 3.40&#x000b1;0.60&#x00025; ID/g at 4 d injection, 29&#x00025; of the initial level. Meanwhile, the tumor uptake increased over a 4 d time period for both RICs (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>). The tumor &#x00025;ID/g of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab, was 23.13&#x000b1;3.36 at 1 d which increased to 33.18&#x000b1;1.84 at 4 d; similarly for <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab, the tumor &#x00025;ID/g was 21.24&#x000b1;1.90&#x00025; ID/g at 1 d and increased to 28.93&#x000b1;3.35 4 d post-injection. The <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab uptake in all the three tumor models was HER1-mediated as demonstrated by receptor-blocking experiments performed by co-injecting 0.1 mg of the corresponding unlabeled mAb (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><span>Fig. 1</span></a>). In mice bearing NCI-H226 (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><span>Fig. 1A</span></a>), MSTO-211H (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><span>Fig. 1B</span></a>) or NCI-2052 (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><span>Fig. 1C</span></a>) tumors, the tumor &#x00025; ID/g at 3 d was 36.5&#x000b1;2.1, 23.4&#x000b1;0.9 and 18.2&#x000b1;1.8, respectively, after i.v. injection of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab. The corresponding tumor &#x00025; ID/g in mice co-injected with 0.1 mg of panitumumab was 14.1&#x000b1;1.1, 12.7&#x000b1;1.0 and 8.3&#x000b1;0.8, respectively, at the same time point, thus demonstrating specificity of the <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab. Similarly, for <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab, the tumor &#x00025; ID/g at 3 d was 29.4&#x000b1;2.5, 22.8&#x000b1;6.2 and 19.1&#x000b1;1.9, respectively, and the corresponding tumor &#x00025; ID/g in mice co-injected with 0.1 mg of cetuximab was 8.2&#x000b1;0.7, 10.0&#x000b1;2.3 and 9.2&#x000b1;0.3, respectively, at the same time point. The values were significantly different (<em>p</em> &#x0003c;0.05) between unblocked and blocked groups for each tumor type and for both RICs. Although both RICs demonstrated HER1-mediated targeting characteristics, subtle and noteworthy differences in organ uptake were observed at different time points after the injection (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>). At 1 and 2 d after injection, the liver uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab was significantly greater (<em>p</em>&#x0200a;=&#x0200a;0.007 and 0.040 at 1 and 2 d, respectively) than the liver uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab in the same tumor model (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>). However, at 4 d after injection, the blood, spleen, kidney, lung and heart uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab was significantly greater than the uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab in those organs in the same tumor model (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>). Inter-tumor differences were observed too. The liver uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab was greater in mice bearing NCI-H226 tumors than in mice bearing MSTO-211H tumors; however, the same phenomenon was not observed with <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002" co-legend-rid="lgnd_pone-0018198-g002"><span>Fig. 2A and B</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140503903587872"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3064677_pone.0018198.g001.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0018198.g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3064677/bin/pone.0018198.g001.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140503903587872"><a target="object" rel="noopener" href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0018198-g001"><div><a class="figpopup" href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>HER1-specificity of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.</strong><p>Receptor-meditated uptake of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab in selected organs of female athymic (NCr) <em>nu/nu</em> mice bearing NCI-H226 (<strong>A</strong>), MSTO-211H (<strong>B</strong>) and NCI-H2052 tumor xenografts (<strong>C</strong>). Biodistribution data were obtained 3 d after injection. All values are expressed as &#x00025; ID/g. Data represent the mean value &#x000b1; SEM from at least three determinations. <sup>&#x0002a;</sup>Receptor blocking studies were performed by co-injecting 0.1 mg mAb with the radiotracer. Values obtained from the blocking studies were significantly lower than the unblocked studies (<em>p</em>&#x0003c;0.05) demonstrating receptor-mediated accumulation in the tumors.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="pone-0018198-g002" co-legend-rid="lgnd_pone-0018198-g002"><a href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140503902003184"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3064677_pone.0018198.g002.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0018198.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3064677/bin/pone.0018198.g002.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140503902003184"><a target="object" rel="noopener" href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0018198-g002"><div><a class="figpopup" href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>PET imaging of mesothelioma with <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.</strong><p>Representative reconstructed and processed maximum intensity projections of female athymic (NCr) <em>nu/nu</em> mouse bearing NCI-226, MSTO-211H and NCI-H2052 tumor xenografts. Mice represented in the images were injected i.v. via the tail vein with 1.7&#x02013;1.9 MBq/&#x0003c;5 &#x000b5;g of the radioimmunoconjugate or co-injected with 0.1 mg excess mAb. The scale represents &#x00025; maximum and minimum threshold intensity. <sup>&#x0002a;</sup>Receptor blocking studies were performed by co-injecting 0.1 mg excess mAb with the corresponding radioimmunoconjugate.</p></div></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="pone-0018198-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Biodistribution of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.</strong></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Organs</td><td colspan="2" align="left" rowspan="1">1 d</td><td colspan="2" align="left" rowspan="1">2 d</td><td colspan="2" align="left" rowspan="1">3 d</td><td colspan="2" align="left" rowspan="1">4 d</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<strong>Blood</strong>
</td><td align="left" rowspan="1" colspan="1">12.06&#x000b1;1.26</td><td align="left" rowspan="1" colspan="1">11.70&#x000b1;1.44</td><td align="left" rowspan="1" colspan="1">8.59&#x000b1;1.62</td><td align="left" rowspan="1" colspan="1">8.16&#x000b1;0.88</td><td align="left" rowspan="1" colspan="1">7.55&#x000b1;0.92</td><td align="left" rowspan="1" colspan="1">5.66&#x000b1;0.99</td><td align="left" rowspan="1" colspan="1">6.94&#x000b1;1.09</td><td align="left" rowspan="1" colspan="1">3.40&#x000b1;0.60<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor</strong>
</td><td align="left" rowspan="1" colspan="1">23.13&#x000b1;3.36</td><td align="left" rowspan="1" colspan="1">21.24&#x000b1;1.90</td><td align="left" rowspan="1" colspan="1">27.23&#x000b1;2.18</td><td align="left" rowspan="1" colspan="1">24.69&#x000b1;1.99</td><td align="left" rowspan="1" colspan="1">36.55&#x000b1;2.04</td><td align="left" rowspan="1" colspan="1">29.43&#x000b1;2.53</td><td align="left" rowspan="1" colspan="1">33.18&#x000b1;1.84</td><td align="left" rowspan="1" colspan="1">28.93&#x000b1;3.35</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Liver</strong>
</td><td align="left" rowspan="1" colspan="1">7.38&#x000b1;0.83</td><td align="left" rowspan="1" colspan="1">13.15&#x000b1;1.21<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">6.64&#x000b1;0.61</td><td align="left" rowspan="1" colspan="1">9.53&#x000b1;0.93<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">6.35&#x000b1;0.82</td><td align="left" rowspan="1" colspan="1">8.77&#x000b1;0.91</td><td align="left" rowspan="1" colspan="1">5.04&#x000b1;0.32</td><td align="left" rowspan="1" colspan="1">5.90&#x000b1;0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Spleen</strong>
</td><td align="left" rowspan="1" colspan="1">4.69&#x000b1;1.04</td><td align="left" rowspan="1" colspan="1">3.96&#x000b1;0.51</td><td align="left" rowspan="1" colspan="1">4.75&#x000b1;0.68</td><td align="left" rowspan="1" colspan="1">3.80&#x000b1;0.49</td><td align="left" rowspan="1" colspan="1">4.05&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">3.58&#x000b1;0.59</td><td align="left" rowspan="1" colspan="1">4.22&#x000b1;0.28</td><td align="left" rowspan="1" colspan="1">1.48&#x000b1;0.25<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Kidney</strong>
</td><td align="left" rowspan="1" colspan="1">3.45&#x000b1;0.71</td><td align="left" rowspan="1" colspan="1">3.61&#x000b1;0.46</td><td align="left" rowspan="1" colspan="1">2.58&#x000b1;0.18</td><td align="left" rowspan="1" colspan="1">2.55&#x000b1;0.21</td><td align="left" rowspan="1" colspan="1">2.69&#x000b1;0.56</td><td align="left" rowspan="1" colspan="1">3.06&#x000b1;0.16</td><td align="left" rowspan="1" colspan="1">2.35&#x000b1;0.18</td><td align="left" rowspan="1" colspan="1">1.53&#x000b1;0.15<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Lungs</strong>
</td><td align="left" rowspan="1" colspan="1">5.96&#x000b1;1.39</td><td align="left" rowspan="1" colspan="1">5.12&#x000b1;0.35</td><td align="left" rowspan="1" colspan="1">5.03&#x000b1;2.40</td><td align="left" rowspan="1" colspan="1">3.08&#x000b1;0.23</td><td align="left" rowspan="1" colspan="1">5.67&#x000b1;0.79</td><td align="left" rowspan="1" colspan="1">4.25&#x000b1;0.50</td><td align="left" rowspan="1" colspan="1">4.45&#x000b1;0.17</td><td align="left" rowspan="1" colspan="1">1.92&#x000b1;0.36<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Heart</strong>
</td><td align="left" rowspan="1" colspan="1">3.55&#x000b1;0.76</td><td align="left" rowspan="1" colspan="1">3.75&#x000b1;0.27</td><td align="left" rowspan="1" colspan="1">2.29&#x000b1;0.39</td><td align="left" rowspan="1" colspan="1">1.96&#x000b1;0.12</td><td align="left" rowspan="1" colspan="1">2.81&#x000b1;0.41</td><td align="left" rowspan="1" colspan="1">2.50&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">2.45&#x000b1;0.16</td><td align="left" rowspan="1" colspan="1">1.24&#x000b1;0.14<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Muscle</strong>
</td><td align="left" rowspan="1" colspan="1">1.75&#x000b1;0.21</td><td align="left" rowspan="1" colspan="1">1.54&#x000b1;0.07</td><td align="left" rowspan="1" colspan="1">1.60&#x000b1;0.58</td><td align="left" rowspan="1" colspan="1">1.02&#x000b1;0.13</td><td align="left" rowspan="1" colspan="1">1.11&#x000b1;0.07</td><td align="left" rowspan="1" colspan="1">1.34&#x000b1;0.19</td><td align="left" rowspan="1" colspan="1">1.00&#x000b1;0.13</td><td align="left" rowspan="1" colspan="1">0.63&#x000b1;0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Femur</strong>
</td><td align="left" rowspan="1" colspan="1">2.75&#x000b1;0.18</td><td align="left" rowspan="1" colspan="1">3.04&#x000b1;0.25</td><td align="left" rowspan="1" colspan="1">2.51&#x000b1;0.54</td><td align="left" rowspan="1" colspan="1">2.43&#x000b1;0.13</td><td align="left" rowspan="1" colspan="1">2.85&#x000b1;0.20</td><td align="left" rowspan="1" colspan="1">2.97&#x000b1;0.76</td><td align="left" rowspan="1" colspan="1">2.52&#x000b1;0.23</td><td align="left" rowspan="1" colspan="1">2.70&#x000b1;0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tail</strong>
</td><td align="left" rowspan="1" colspan="1">2.12&#x000b1;0.42</td><td align="left" rowspan="1" colspan="1">2.10&#x000b1;0.05</td><td align="left" rowspan="1" colspan="1">1.49&#x000b1;0.54</td><td align="left" rowspan="1" colspan="1">2.27&#x000b1;0.24</td><td align="left" rowspan="1" colspan="1">1.59&#x000b1;0.27</td><td align="left" rowspan="1" colspan="1">2.05&#x000b1;0.14</td><td align="left" rowspan="1" colspan="1">2.11&#x000b1;0.18</td><td align="left" rowspan="1" colspan="1">1.84&#x000b1;0.29</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140503902362496"><a target="object" rel="noopener" href="/pmc/articles/PMC3064677/table/pone-0018198-t001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt101"><sup></sup>
<em>In vivo</em> biodistribution of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab injected i.v. via tail vein of female athymic (NCr) <em>nu</em>/<em>nu</em> mice bearing NCI-H226 tumor xenograft. Biodistribution data were obtained at 1, 2, 3 and 4 d after injection. All values are expressed as &#x00025; ID/g. Data represents the mean value &#x000b1; SEM from at least four determinations.</div><div id="nt102"><sup>#</sup>Values obtained from <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab were significantly different from each other (<em>p</em>&#x0003c;0.05).</div></div></div></div><div id="s2b2" class="sec sec-last"><p></p><h4 id="s2b2title" class="inline">PET imaging studies and pharmacokinetic analysis </h4><p class="p p-first">Small animal PET imaging studies were performed in female athymic mice bearing NCI-H226, MSTO-211H and NCI-H2052 tumor xenografts injected with 1.7&#x02013;1.9 MBq of RIC or RIC co-injected with 0.1 mg excess of the corresponding mAb (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002" co-legend-rid="lgnd_pone-0018198-g002"><span>Figure 2</span></a>). Tumors were clearly visualized in maximum intensity projections of mice imaged from 0.5 to 3 d after injection of either of the RICs. The tumor-to-background ratios improved over the period primarily due to the decrease and clearance of the radioactivity in blood, liver and background while the tumor uptake increased. In contrast, when 0.1 mg of excess mAb was co-injected with its corresponding RIC, tumors were poorly visualized due to receptor-specific blockage, demonstrating the HER1-specificity of both radioimmunoconjugates also shown in quantitative information obtained from PET studies (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g003" rid-ob="ob-pone-0018198-g003" co-legend-rid="lgnd_pone-0018198-g003"><span>Figure 3</span></a>). Significant differences were found between the liver uptake of mice injected with <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and mice injected with <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab, particularly in the NCI-H226 and MSTO-211H tumor models. The liver clearance of the <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab was slower than that of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab therefore resulting in lower tumor-liver ratios than <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm" id="pone-0018198-g003" co-legend-rid="lgnd_pone-0018198-g003"><a href="/pmc/articles/PMC3064677/figure/pone-0018198-g003/" target="figure" rid-figpopup="pone-0018198-g003" rid-ob="ob-pone-0018198-g003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div class="figure" data-largeobj="" data-largeobj-link-rid="largeobj_idm140503909989344"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=3064677_pone.0018198.g003.jpg" target="tileshopwindow" rel="noopener"><div class="ts_bar small" title="Click on image to zoom"></div><img loading="lazy" alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0018198.g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC3064677/bin/pone.0018198.g003.jpg" /></a></div><div class="largeobj-link align_right" id="largeobj_idm140503909989344"><a target="object" rel="noopener" href="/pmc/articles/PMC3064677/figure/pone-0018198-g003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0018198-g003"><div><a class="figpopup" href="/pmc/articles/PMC3064677/figure/pone-0018198-g003/" target="figure" rid-figpopup="pone-0018198-g003" rid-ob="ob-pone-0018198-g003">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Time-activity curves obtained from quantitative PET imaging of mesothelioma with <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.</strong><p>PET generated time-activity curves in mice bearing (A) NCI-H226, (B) MSTO-211H and (C) NCI-H2052 tumor xenografts. <sup>&#x0002a;</sup>Receptor blocking studies were performed by co-injecting 0.1 mg excess mAb with the corresponding radioimmunoconjugate.</p></div></div></div><p class="p">Pharmacokinetic analyses performed on biodistribution and PET derived values, and from values obtained from serial blood sampling revealed further differences between <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>). The blood T<sub>&#x000bd;</sub>&#x003b1; for <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab was significantly slower than that of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab; however, no significant difference was observed between the two RICs in the T<sub>&#x000bd;</sub>&#x003b2; phase. The <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab blood AUC<sub>[0&#x02192;4]</sub> values were slightly greater than <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab values, however the difference was not statistically significant. For both RICs, the tumor AUC<sub>[0&#x02192;4]</sub> value were highest for mice bearing NCI-H266 tumor xenografts and lowest for mice bearing NCI-H2052 tumor xenografts (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>). For each tumor model, the <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab liver AUC<sub>[0&#x02192;4]</sub> values were significantly greater than that of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab. The <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab tumor AUC<sub>[0&#x02192;4]</sub>: liver AUC<sub>[0&#x02192;4]</sub> ratio values were 1.7, 2.5 and 1.4 times greater than values obtained from <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab in mice bearing NCI-H226, MSTO-211H and NCI-H2052, respectively (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>). The mean residence times were identical for all of the tumor models and RICs. For both RICs, PET derived tumor AUC<sub>[0&#x02192;3]</sub> values were significantly greater than corresponding tumor AUC<sub>[0&#x02192;3]</sub> values derived from blocking experiments with 0.1 mg excess mAb co-injection (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a> and <a href="/pmc/articles/PMC3064677/figure/pone-0018198-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g003" rid-ob="ob-pone-0018198-g003" co-legend-rid="lgnd_pone-0018198-g003"><span>Figure 3</span></a>), thus again demonstrating HER1-mediated tumor accumulation over the 3 d study period. The organ uptake values quantified by PET were closely related (r<sup>2</sup>&#x0200a;=&#x0200a;0.92, <em>p</em>&#x0200a;=&#x0200a;0.90, n&#x0200a;=&#x0200a;76) to values determined by <em>ex vivo</em> biodistribution studies.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap anchored whole_rhythm" id="pone-0018198-t002"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Pharmacokinetic characteristics of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.</strong></div><div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1">Pharmacokinetic characteristics</td><td colspan="2" align="left" rowspan="1">NCI-H226</td><td colspan="2" align="left" rowspan="1">MSTO-211H</td><td colspan="2" align="left" rowspan="1">NCI-H2052</td></tr><tr><td align="left" rowspan="1" colspan="1">
<sup>86</sup>Y labeled antibody</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetixumab</td><td align="left" rowspan="1" colspan="1">Panitumumab</td><td align="left" rowspan="1" colspan="1">Cetuximab</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<strong><em>In vitro</em></strong>
<strong> expression as MFI (&#x00025;)</strong>
</td><td align="left" rowspan="1" colspan="1">375.4 (99.85)</td><td align="left" rowspan="1" colspan="1">345.4 (99.7)</td><td align="left" rowspan="1" colspan="1">217.2 (87.2)</td><td align="left" rowspan="1" colspan="1">224.4 (79.9)</td><td align="left" rowspan="1" colspan="1">330.5 (93.0)</td><td align="left" rowspan="1" colspan="1">337.5 (90.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Blood clearance (h)</strong>
</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;3.1&#x000b1;1.4&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;62.1&#x000b1;16.1</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;0.9&#x000b1;0.2<sup>#</sup>&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;43.5&#x000b1;11.5</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;3.0&#x000b1;0.9&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;58.1&#x000b1;10.2</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;1.1&#x000b1;0.1<sup>#</sup>&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;47.8&#x000b1;11.9</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;2.6&#x000b1;1.2&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;86.9&#x000b1;24.3</td><td align="left" rowspan="1" colspan="1">&#x003b1;- t<sub>1/2</sub>&#x0200a;=&#x0200a;0.9&#x000b1;0.3<sup>#</sup>&#x003b2;- t<sub>1/2</sub>&#x0200a;=&#x0200a;46.1&#x000b1;9.8</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Blood AUC<sub>[0&#x02192;4]</sub> (&#x00025;ID<sup>.</sup>d<sup>.</sup>g<sup>&#x02212;1</sup>)</strong>
</td><td align="left" rowspan="1" colspan="1">26.6&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">21.7&#x000b1;2.3</td><td align="left" rowspan="1" colspan="1">30.3&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">29.7&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">30.3&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">29.7&#x000b1;3.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor AUC<sub>[0&#x02192;4]</sub> (&#x00025;ID<sup>.</sup>d<sup>.</sup>g<sup>&#x02212;1</sup>)</strong>
</td><td align="left" rowspan="1" colspan="1">105.7&#x000b1;5.8</td><td align="left" rowspan="1" colspan="1">90.4&#x000b1;8.2</td><td align="left" rowspan="1" colspan="1">69.8&#x000b1;8.5</td><td align="left" rowspan="1" colspan="1">63.0&#x000b1;4.2</td><td align="left" rowspan="1" colspan="1">60.6&#x000b1;3.4</td><td align="left" rowspan="1" colspan="1">58.6&#x000b1;2.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Liver AUC<sub>[0&#x02192;4]</sub> (&#x00025;ID<sup>.</sup>d<sup>.</sup>g<sup>&#x02212;1</sup>)</strong>
</td><td align="left" rowspan="1" colspan="1">24.2&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">35.1&#x000b1;3.2<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">18.2&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">40.6&#x000b1;3.3<sup>#</sup>
</td><td align="left" rowspan="1" colspan="1">29.7&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">40.7&#x000b1;3.4<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor PET AUC<sub>[0&#x02192;3]</sub> (&#x00025;ID<sup>.</sup>d<sup>.</sup>cc<sup>&#x02212;1</sup>)</strong>
</td><td align="left" rowspan="1" colspan="1">72.3&#x000b1;4.8</td><td align="left" rowspan="1" colspan="1">60.7&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">46.9&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">43.7&#x000b1;3.2</td><td align="left" rowspan="1" colspan="1">41.2&#x000b1;3.9</td><td align="left" rowspan="1" colspan="1">40.6&#x000b1;2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor PET AUC<sub>[0&#x02192;3]</sub> (&#x00025;ID<sup>.</sup>d<sup>.</sup>cc<sup>&#x02212;1</sup>)</strong>
<sup>&#x0002a;</sup>
</td><td align="left" rowspan="1" colspan="1">26.1&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">22.3&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">25.0&#x000b1;1.2</td><td align="left" rowspan="1" colspan="1">22.5&#x000b1;1.0</td><td align="left" rowspan="1" colspan="1">25.0&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">21.6&#x000b1;1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor AUC<sub>[0&#x02192;4]</sub>: Blood AUC<sub>[0&#x02192;4]</sub></strong>
</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">4.2</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">2.0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor AUC<sub>[0&#x02192;4]</sub>: Liver AUC<sub>[0&#x02192;4]</sub></strong>
</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">3.8</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor AUMC<sub>[0&#x02192;4]</sub> (&#x00025;ID<sup>.</sup> d<sup>2.</sup>g<sup>-1</sup>)</strong>
</td><td align="left" rowspan="1" colspan="1">253.6&#x000b1;16.2</td><td align="left" rowspan="1" colspan="1">216.8&#x000b1;18.4</td><td align="left" rowspan="1" colspan="1">172.5&#x000b1;18.1</td><td align="left" rowspan="1" colspan="1">151.0&#x000b1;11.2</td><td align="left" rowspan="1" colspan="1">152.3&#x000b1;8.1</td><td align="left" rowspan="1" colspan="1">146.4&#x000b1;9.9</td></tr><tr><td align="left" rowspan="1" colspan="1">
<strong>Tumor MRT (d)</strong>
</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">2.5</td></tr></tbody></table></div><div class="largeobj-link align_right" id="largeobj_idm140503944962752"><a target="object" rel="noopener" href="/pmc/articles/PMC3064677/table/pone-0018198-t002/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt103"><sup></sup>Pharmacokinetic characteristics of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab injected i.v. via tail vein of female athymic (NCr) <em>nu</em>/<em>nu</em> mice bearing NCI-H226, MSTO-211H and NCI-H2052 tumor xenografts. Data represent the mean values from three to six determinations.</div><div id="nt104"><sup></sup>&#x0002a;Receptor blocking studies were performed by co-injecting 0.1 mg mAb with the radiotracer. Values obtained from the blocking studies were significantly lower than the unblocked studies (<em>p</em>&#x0003c;0.05) demonstrating receptor-mediated accumulation in the tumors.</div><div id="nt105"><sup>#</sup>Values obtained from <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab were significantly different from each other (<em>p</em>&#x0003c;0.05).</div></div></div></div></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Discussion</h2><p class="p p-first">Information available from the Surveillance, Epidemiology and End Results (SEER) confirms that the incidence of mesothelioma has increased in recent years from almost nil to the current 2500&#x02013;3000 cases per year in the USA <a href="#pone.0018198-Yang1" rid="pone.0018198-Yang1" class=" bibr popnode">[1]</a>. Diagnosis of MM is difficult and current treatments do not provide significant improvements in survival. Computed Tomography (CT) has been widely used as the primary imaging modality for the diagnosis, staging, and monitoring of therapeutic response in MM. More recently, MRI and PET imaging with FDG have gained popularity for imaging MM because of the excellent resolution and superiority in the differentiation of malignant from benign disease <a href="#pone.0018198-Heelan1" rid="pone.0018198-Heelan1" class=" bibr popnode">[32]</a>, <a href="#pone.0018198-Lee2" rid="pone.0018198-Lee2" class=" bibr popnode">[33]</a>, <a href="#pone.0018198-Nowak1" rid="pone.0018198-Nowak1" class=" bibr popnode">[34]</a>. A prospective study comprising 32 patients, 19 with malignant and 13 with benign disease, found that FDG PET had a high negative predictive value of 92&#x00025;. FDG PET imaging showed an absence of FDG uptake, and correctly classified 31/35 benign lesions. Nevertheless, the usefulness of FDG is limited by its uptake in inflammatory cells such as macrophages and activated lymphocytes, which can cause false-positive results as seen in cases of parapneumonic effusion, tuberculous and uraemic pleural disease <a href="#pone.0018198-Benamore1" rid="pone.0018198-Benamore1" class=" bibr popnode">[35]</a>, <a href="#pone.0018198-Kramer1" rid="pone.0018198-Kramer1" class=" bibr popnode">[36]</a>. In spite of recent advances in the diagnosis of MM, therapeutic outcomes have not greatly improved. Surgical resection and adjuvant radiation therapy remain the mainstay of treatment for patients with resectable MM <a href="#pone.0018198-Tsao1" rid="pone.0018198-Tsao1" class=" bibr popnode">[37]</a>.</p><p>Occupational exposure to asbestos remains the major risk factor for MM. This exposure has been demonstrated to be associated with increased HER1 activation and expression <a href="#pone.0018198-Pache1" rid="pone.0018198-Pache1" class=" bibr popnode">[7]</a>, <a href="#pone.0018198-Zanella1" rid="pone.0018198-Zanella1" class=" bibr popnode">[8]</a>, <a href="#pone.0018198-Faux1" rid="pone.0018198-Faux1" class=" bibr popnode">[9]</a>. Therefore, HER1-targeted imaging can play a complimentary role in a better understanding of asbestos-induced mesothelioma. While traditional targeting of HER1 for therapy has not been successful, it is feasible that HER1 binding molecules could be used as vectors to effectively deliver imageable or cytotoxic radioactive payloads differentially to MM cells to potentially improve diagnostic as well as therapeutic outcomes. Towards this end, the <em>in vivo</em> targeting characteristics of two HER1-binding monoclonal antibodies, cetuximab and panitumumab, each labeled with <sup>86</sup>Y, were comparatively evaluated as potential diagnostics by PET imaging, and to select a potential candidate for evaluation in monoclonal antibody targeted RIT applications.</p><p>
<em>In vitro</em> HER1 expression was observed in four MM cell lines evaluated (<a href="#pone.0018198.s001" rid="pone.0018198.s001" class=" supplementary-material">Table S1</a>) similar to the clinical findings of HER1 over-expression in majority of MM <a href="#pone.0018198-Gaafar1" rid="pone.0018198-Gaafar1" class=" bibr popnode">[10]</a>, <a href="#pone.0018198-Kothmaier1" rid="pone.0018198-Kothmaier1" class=" bibr popnode">[11]</a>, <a href="#pone.0018198-Edwards1" rid="pone.0018198-Edwards1" class=" bibr popnode">[12]</a>, <a href="#pone.0018198-Okuda1" rid="pone.0018198-Okuda1" class=" bibr popnode">[13]</a>. HER1-specific tumor targeting was observed in all three xenograft tumor models evaluated (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g001" rid-ob="ob-pone-0018198-g001" co-legend-rid="lgnd_pone-0018198-g001"><span>Figs. 1</span></a>, <a href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002" co-legend-rid="lgnd_pone-0018198-g002"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -0.5em;">,2,</span></span><span>2</span></a>, and <a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>) supporting the hypothesis that HER1 targeting can be used for imaging and radionuclide therapy of MM. Although both radiolabeled cetuximab and panitumumab demonstrated <em>in vivo</em> HER1-targeting characteristics, disparities were observed with blood clearance and non-target organ uptake (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a> and <a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2).</span></span><span>2</span></a>). Cetuximab is a chimeric IgG<sub>1</sub> mAb, whereas panitumumab is a fully human IgG<sub>2</sub> mAb and binds to a different epitope of the HER1 antigen than cetuximab. Antibodies are usually cleared through their interaction with the Fc receptors expressed on cells of the reticuloendothelial system <a href="#pone.0018198-Lobo1" rid="pone.0018198-Lobo1" class=" bibr popnode">[38]</a>, <a href="#pone.0018198-Wang1" rid="pone.0018198-Wang1" class=" bibr popnode">[39]</a>. The slower first-phase blood clearance of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab may be attributed to the fact that panitumumab is an IgG<sub>2</sub> whereas cetuximab is an IgG<sub>1</sub>. IgG<sub>2</sub> antibodies have lower affinity and binding to the Fc-gamma receptors than the IgG<sub>1</sub> and therefore are cleared more slowly by this mechanism <a href="#pone.0018198-Lobo1" rid="pone.0018198-Lobo1" class=" bibr popnode">[38]</a>, <a href="#pone.0018198-Wang1" rid="pone.0018198-Wang1" class=" bibr popnode">[39]</a>. As observed in the biodistribution (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t001" rid-ob="ob-pone-0018198-t001" co-legend-rid=""><span>Table 1</span></a>) and PET imaging studies (<a href="/pmc/articles/PMC3064677/figure/pone-0018198-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0018198-g002" rid-ob="ob-pone-0018198-g002" co-legend-rid="lgnd_pone-0018198-g002"><span>Fig. 2</span></a> and <a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>), the liver uptake and accumulation of <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab was significantly greater than that of <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab in all three xenograft tumor models, and as a result, tumor to liver ratios were better for <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab than <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab (<a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>Table 2</span></a>). For <sup>90</sup>Y- RIT, the data obtained from this pre-clinical study indicate that RIT with <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab and <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab will result in similar tumor accumulation; however, that same data also suggests that <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab will result in higher radiation doses to the liver than <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab due significantly greater cumulative activity in liver (presented as AUC in <a href="/pmc/articles/PMC3064677/table/pone-0018198-t002/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0018198-t002" rid-ob="ob-pone-0018198-t002" co-legend-rid=""><span>table 2</span></a>). Therefore, <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab may be a more favorable candidate for RIT than <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab due to higher tumor:liver that may result in lower radiation doses to the normal organs than <sup>90</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab. Previous clinical study with <sup>111</sup>In labeled 225 (murine version of cetuximab) suggests the presence of HER1 receptor in the liver based on the dose-dependent liver uptake and clearance of the <sup>111</sup>In labeled murine 225. However, a study performed with radiolabeled chimeric mAb, C225 (cetuximab) concluded that the residence time in the liver appeared to be longer in patients with cold loading than in those without. One explanation could indeed be that the liver does not have C225 binding sites, but simply metabolically extracts whatever is not taken up elsewhere in the body. In the pre-clinical study performed in the report, the uptake in liver was not blocked by co-injecting excess cetuximab and panitumumab, suggesting the lack of cetuximab and panitumumab binding sites in mouse liver, which in part concurs with the information provided by the manufacturer of cetuximab, ImClone Systems. Therefore, the differences in liver zzzuptake may be a function of radiometabolities and/or Fc-gamma interactions of cetuximab and panitumumab. These differences can also have a significant impact for targeting intrapleural and intraperitoneal MM with respect to signal to noise ratios as well as radiation doses delivered to the liver, particularly in the setting of radionuclide therapy.</p><p class="p">For this reason, panitumumab presents as a better alternative than cetuximab for HER1-targeted imaging and RIT. The HER1- targeting characteristics of radiolabeled panitumumab shown here points to its potential as a great diagnostic tool for detection and staging of MM. The results also point to the potential of panitumumab as a vehicle for delivering therapeutic radioactivity to HER1-expressing MM tumors. This approach to MM therapy should improve outcomes for HER1 over-expressing tumors that have not responded to classical HER1 therapy with TKIs and monoclonal antibodies due to resistance.</p><div id="s3a" class="sec sec-last"><h3 id="s3atitle">Conclusions</h3><p class="p p-first-last">In this study, the more favorable HER1-targeting characteristics of <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-panitumumab than <sup>86</sup>Y- CHX-A&#x02019;&#x02019;-DTPA-cetuximab for non-invasive staging and assessment of the HER1 status of MM has been demonstrated. HER1-targeted immunoPET can be complimentary to CT and MRI for diagnosis and prognosis of MM. Valuable molecular information on further understanding the role of HER1 in asbestos-induced MM may also be garnered. In conclusion, the strategy to target asbestos-induced HER1 over-expression for molecular imaging and radionuclide therapy warrants further investigation for clinical translation and improved clinical outcomes and management of MM.</p></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Materials and Methods</h2><div id="s4a" class="sec sec-first"><h3 id="s4atitle">Cell lines and tissue culture</h3><p class="p p-first-last">NCI-H226, NCI-H2052, NCI-H2452 and MSTO-211H human mesothelioma cells were purchased from American Type Culture Collection (Manassas, VA). All cell lines were grown as a monolayer at 37&#x000b0;C, in a humidified atmosphere of 5&#x00025; CO<sub>2</sub> and 95&#x00025; air. Cells were cultured in RPMI-1640 media containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L sodium bicarbonate. All media were additionally supplemented with 10&#x00025; FetalPlex (Gemini Bio-Products, Inc, Woodland, CA, USA). Media and supplements were obtained from Invitrogen (Carlsbad, CA, USA) and Lonza (Walkersville, MD, USA).</p></div><div id="s4b" class="sec"><h3 id="s4btitle">Flow-Cytometric Analysis</h3><p class="p p-first-last">HER1 expression of the mesothelioma cell lines was evaluated by standard flow-cytometric techniques <a href="#pone.0018198-Milenic2" rid="pone.0018198-Milenic2" class=" bibr popnode">[40]</a>. Briefly, cells were trypsinized, pelleted at 1,500&#x000d7; g for 10 min and re-suspended in phosphate-buffered saline (PBS; pH 7.2) containing 1&#x00025; bovine serum albumin (BSA). The cells (1&#x000d7;10<sup>6</sup> cells in 100 &#x000b5;L of 1&#x00025; BSA in PBS) were added to 12&#x000d7;75 mM polypropylene tubes (Falcon Labware, Franklin Lakes, NJ) along with 1 &#x000b5;g of cetuximab (Erbitux: Bristol-Meyers Squibb Co, Princeton, NJ) or panitumumab (Vectibix: Amgen, Thousand Oaks, CA) in 100 &#x000b5;L. The cells were incubated for 1 h at 4&#x000b0;C, washed three times by adding 2 mL of 1&#x00025; BSA in PBS, pelleting the cells at 1,000&#x000d7; g for 5 min and decanting the supernatant. Following the last wash, 100 &#x000b5;L of FITC-labeled goat anti-human IgG (50 &#x000b5;g/mL; Kirkegaard and Perry, Gaithersburg, MD) was added to the cells and incubated for an additional 1 h at 4&#x000b0;C. The cells were washed three times as before and analyzed (10,000 events) using a FACScalibur (BD Biosciences, San Jose, CA) with CellQuest software. HuM195, an anti-CD33 mAb kindly provided by Dr. Michael McDevitt at Memorial Sloan-Kettering Cancer Center, served as a control mAb.</p></div><div id="s4c" class="sec"><h3 id="s4ctitle">Preparation of radioimmunoconjugates</h3><p class="p p-first-last">The <sup>86</sup>Y was produced by the previously described <sup>86</sup>Sr(p,n)<sup>86</sup>Y reaction using a SrCO<sub>3</sub> target <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>, <a href="#pone.0018198-Garmestani1" rid="pone.0018198-Garmestani1" class=" bibr popnode">[41]</a>. The preparation and quality control of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab and <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab conjugates was performed as previously described <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>, <a href="#pone.0018198-Nayak3" rid="pone.0018198-Nayak3" class=" bibr popnode">[30]</a>.</p></div><div id="s4d" class="sec"><h3 id="s4dtitle">Animal and tumor models</h3><p class="p p-first-last">All animal studies were performed in accordance with the NIH guidelines for the humane use of animals and all procedures were reviewed and approved by the National Cancer Institute Animal Care and Use Committee (Protocol ID: ROB-104/5). Groups of 5&#x02013;8 week old female athymic <em>nu/nu</em> mice (Charles River Laboratory, Wilmington, DE) were injected subcutaneously with 2&#x02013;4&#x000d7;10<sup>6</sup> MSTO-211H, 6&#x02013;10&#x000d7;10<sup>6</sup> NCI-H226, or 6&#x02013;10&#x000d7;10<sup>6</sup> NCI-H2052 cells in 200 &#x000b5;L medium containing 20&#x00025; matrigel.</p></div><div id="s4e" class="sec"><h3 id="s4etitle">Biodistribution and pharmacokinetic studies</h3><p class="p p-first-last">Tumor bearing female athymic mice were intravenously (i.v.) injected with 0.4&#x02013;0.6 MBq (&#x0003c;5 &#x000b5;g) of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab or <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab. To demonstrate HER1-specificity, excess mAb (0.1 mg) was co-injected with the corresponding radioimmunoconjugate (RIC) into an additional set of mice bearing each of the tumor xenografts. At the desired time points, the animals were sacrificed by CO<sub>2</sub> inhalation. Tumor, blood and selected organs were harvested, wet-weighed, and the radioactivity measured in a Wizard 1480 gamma counter (PerkinElmer, Shelton, CT). The percent injected dose per gram (&#x00025; ID/g) of tissue was calculated by comparison with standards representing 10&#x00025; of the injected dose per animal. Non-compartmental pharmacokinetics was performed to determine area under the curve (AUC), area under the first moment curve (AUMC) and the mean residence time (MRT) using trapezoidal integration analysis <a href="#pone.0018198-Gibaldi1" rid="pone.0018198-Gibaldi1" class=" bibr popnode">[42]</a>. The sample size for biodistribution study was equal to or greater than four animals per group.</p></div><div id="s4f" class="sec"><h3 id="s4ftitle">PET imaging studies</h3><p class="p p-first-last">Small animal PET studies were performed using the ATLAS (Advanced Technology Laboratory Animal Scanner) at the National Institutes of Health, Bethesda, MD, USA. Whole body imaging studies (6 bed positions, total acquisition time of 1 h per mouse) were carried out on mice anesthetized with 1.5&#x02013;1.7&#x00025; isoflurane on a temperature-controlled bed as previously described <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>. Tumor bearing female athymic mice were injected i.v. with 1.7&#x02013;1.9 MBq (&#x0003c;5 &#x000b5;g) of <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab or <sup>86</sup>Y-CHX-A&#x02019;&#x02019;-DTPA-panitumumab. To determine HER1-specificity, excess unmodified mAb (0.1 mg) was co-injected with the corresponding RIC. Phantom studies, image acquisition, processing and analysis was performed as previously described <a href="#pone.0018198-Nayak2" rid="pone.0018198-Nayak2" class=" bibr popnode">[29]</a>. After imaging, the mice were euthanized and biodistribution studies were performed to determine the correlation between PET-assessed <em>in vivo</em> &#x00025; ID/cm<sup>3</sup> and biodistribution determined <em>ex vivo</em> &#x00025; ID/g. The sample size for PET imaging study was equal to or greater than three animals per group.</p></div><div id="s4g" class="sec sec-last"><h3 id="s4gtitle">Statistical Analysis</h3><p class="p p-first-last">All numerical data were expressed as the mean of the values &#x000b1; the standard error of mean (SEM). Graphpad Prism version 5 (San Diego, CA, USA) was used for statistical analysis. A <em>p</em> value less than 0.05 was considered statistically significant.</p></div></div><div id="s5" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="s5title">Supporting Information</h2><!--/article/body/sec/--><div class="sec suppmat" id="pone.0018198.s001"><h4>Table S1</h4><p>Relative <em>in vitro</em> expression of HER1 in human mesothelioma cells determined by FACS based assay. MFI &#x0200a;=&#x0200a; mean fluorescence intensity.</p><p>(DOC)</p><div class="sup-box half_rhythm" id="media-a.m.e.b.c"><a href="/pmc/articles/PMC3064677/bin/pone.0018198.s001.doc" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(36K, doc)</sup></div></div></div><div id="fn-group-a.n.a" class="tsec sec"><h2 class="head no_bottom_margin" id="fn-group-a.n.atitle">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="fn-a.n.a.a"><p class="p p-first-last"><strong>Competing Interests: </strong>The authors have declared that no competing interests exist.</p></p><p class="fn sec" id="fn-a.n.a.b"><p class="p p-first-last"><strong>Funding: </strong>The Intramural Research Program of the NIH, NCI, Center for Cancer Research and the United States Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></p></div></div><div id="ref-list-a.n.b" class="tsec sec"><h2 class="head no_bottom_margin" id="ref-list-a.n.btitle">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="pone.0018198-Yang1">1. <span class="element-citation">Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. <span><span class="ref-journal">Curr Treat Options Oncol. </span>2008;<span class="ref-vol">9</span>:147–157.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2717086/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18709470" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Treat+Options+Oncol&amp;title=Mesothelioma+epidemiology,+carcinogenesis,+and+pathogenesis.&amp;author=H+Yang&amp;author=JR+Testa&amp;author=M+Carbone&amp;volume=9&amp;publication_year=2008&amp;pages=147-157&amp;pmid=18709470&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Kamp1">2. <span class="element-citation">Kamp DW. Asbestos-induced lung diseases: an update. <span><span class="ref-journal">Transl Res. </span>2009;<span class="ref-vol">153</span>:143–152.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3544481/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19304273" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Transl+Res&amp;title=Asbestos-induced+lung+diseases:+an+update.&amp;author=DW+Kamp&amp;volume=153&amp;publication_year=2009&amp;pages=143-152&amp;pmid=19304273&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Robinson1">3. <span class="element-citation">Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. <span><span class="ref-journal">Lancet. </span>2005;<span class="ref-vol">366</span>:397–408.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16054941" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Malignant+mesothelioma.&amp;author=BW+Robinson&amp;author=AW+Musk&amp;author=RA+Lake&amp;volume=366&amp;publication_year=2005&amp;pages=397-408&amp;pmid=16054941&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Vogelzang1">4. <span class="element-citation">Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. <span><span class="ref-journal">Semin Oncol. </span>2005;<span class="ref-vol">32</span>:336–350.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15988688" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Semin+Oncol&amp;title=New+agents+in+the+management+of+advanced+mesothelioma.&amp;author=NJ+Vogelzang&amp;author=C+Porta&amp;author=L+Mutti&amp;volume=32&amp;publication_year=2005&amp;pages=336-350&amp;pmid=15988688&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Robinson2">5. <span class="element-citation">Robinson BW, Lake RA. Advances in malignant mesothelioma. <span><span class="ref-journal">N Engl J Med. </span>2005;<span class="ref-vol">353</span>:1591–1603.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16221782" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Advances+in+malignant+mesothelioma.&amp;author=BW+Robinson&amp;author=RA+Lake&amp;volume=353&amp;publication_year=2005&amp;pages=1591-1603&amp;pmid=16221782&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Lee1">6. <span class="element-citation">Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. <span><span class="ref-journal">Cancer. </span>2007;<span class="ref-vol">109</span>:1454–1461.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17348013" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Update+on+the+molecular+biology+of+malignant+mesothelioma.&amp;author=AY+Lee&amp;author=DJ+Raz&amp;author=B+He&amp;author=DM+Jablons&amp;volume=109&amp;publication_year=2007&amp;pages=1454-1461&amp;pmid=17348013&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Pache1">7. <span class="element-citation">Pache JC, Janssen YM, Walsh ES, Quinlan TR, Zanella CL, et al. Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers. <span><span class="ref-journal">Am J Pathol. </span>1998;<span class="ref-vol">152</span>:333–340.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1857975/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9466557" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Increased+epidermal+growth+factor-receptor+protein+in+a+human+mesothelial+cell+line+in+response+to+long+asbestos+fibers.&amp;author=JC+Pache&amp;author=YM+Janssen&amp;author=ES+Walsh&amp;author=TR+Quinlan&amp;author=CL+Zanella&amp;volume=152&amp;publication_year=1998&amp;pages=333-340&amp;pmid=9466557&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Zanella1">8. <span class="element-citation">Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. <span><span class="ref-journal">Cancer Res. </span>1996;<span class="ref-vol">56</span>:5334–5338.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8968079" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Asbestos+causes+stimulation+of+the+extracellular+signal-regulated+kinase+1+mitogen-activated+protein+kinase+cascade+after+phosphorylation+of+the+epidermal+growth+factor+receptor.&amp;author=CL+Zanella&amp;author=J+Posada&amp;author=TR+Tritton&amp;author=BT+Mossman&amp;volume=56&amp;publication_year=1996&amp;pages=5334-5338&amp;pmid=8968079&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Faux1">9. <span class="element-citation">Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. <span><span class="ref-journal">Carcinogenesis. </span>2000;<span class="ref-vol">21</span>:2275–2280.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11133818" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Carcinogenesis&amp;title=Increased+expression+of+epidermal+growth+factor+receptor+in+rat+pleural+mesothelial+cells+correlates+with+carcinogenicity+of+mineral+fibres.&amp;author=SP+Faux&amp;author=CE+Houghton&amp;author=A+Hubbard&amp;author=G+Patrick&amp;volume=21&amp;publication_year=2000&amp;pages=2275-2280&amp;pmid=11133818&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Gaafar1">10. <span class="element-citation">Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. <span><span class="ref-journal">Lung Cancer. </span>2010;<span class="ref-vol">70</span>:43–50.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20347505" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lung+Cancer&amp;title=Tissue+and+serum+EGFR+as+prognostic+factors+in+malignant+pleural+mesothelioma.&amp;author=R+Gaafar&amp;author=A+Bahnassy&amp;author=I+Abdelsalam&amp;author=MM+Kamel&amp;author=A+Helal&amp;volume=70&amp;publication_year=2010&amp;pages=43-50&amp;pmid=20347505&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Kothmaier1">11. <span class="element-citation">Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, et al.  Thorax; 2007. EGFR And PDGFR Differentially Promote Growth In Malignant Epitheloid Mesothelioma Of Short- And Long-term Survivors. [<a href="https://pubmed.ncbi.nlm.nih.gov/18086752" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Kothmaier+H+Quehenberger+F+Halbwedl+I+Morbini+P+Demirag+F+2007+EGFR+And+PDGFR+Differentially+Promote+Growth+In+Malignant+Epitheloid+Mesothelioma+Of+Short-+And+Long-term+Survivors.+Thorax+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Edwards1">12. <span class="element-citation">Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. <span><span class="ref-journal">Lung Cancer. </span>2006;<span class="ref-vol">54</span>:399–407.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17049671" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lung+Cancer&amp;title=EGFR+expression:+associations+with+outcome+and+clinicopathological+variables+in+malignant+pleural+mesothelioma.&amp;author=JG+Edwards&amp;author=DE+Swinson&amp;author=JL+Jones&amp;author=DA+Waller&amp;author=KJ+O'Byrne&amp;volume=54&amp;publication_year=2006&amp;pages=399-407&amp;pmid=17049671&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Okuda1">13. <span class="element-citation">Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. <span><span class="ref-journal">J Cancer Res Clin Oncol. </span>2008;<span class="ref-vol">134</span>:1105–1111.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18392851" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Cancer+Res+Clin+Oncol&amp;title=Epidermal+growth+factor+receptor+gene+mutation,+amplification+and+protein+expression+in+malignant+pleural+mesothelioma.&amp;author=K+Okuda&amp;author=H+Sasaki&amp;author=O+Kawano&amp;author=H+Yukiue&amp;author=T+Yokoyama&amp;volume=134&amp;publication_year=2008&amp;pages=1105-1111&amp;pmid=18392851&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Destro1">14. <span class="element-citation">Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. <span><span class="ref-journal">Lung Cancer. </span>2006;<span class="ref-vol">51</span>:207–215.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16384623" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lung+Cancer&amp;title=EGFR+overexpression+in+malignant+pleural+mesothelioma.+An+immunohistochemical+and+molecular+study+with+clinico-pathological+correlations.&amp;author=A+Destro&amp;author=GL+Ceresoli&amp;author=M+Falleni&amp;author=PA+Zucali&amp;author=E+Morenghi&amp;volume=51&amp;publication_year=2006&amp;pages=207-215&amp;pmid=16384623&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Garland1">15. <span class="element-citation">Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:2406–2413.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17557954" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Phase+II+study+of+erlotinib+in+patients+with+malignant+pleural+mesothelioma:+a+Southwest+Oncology+Group+Study.&amp;author=LL+Garland&amp;author=C+Rankin&amp;author=DR+Gandara&amp;author=SE+Rivkin&amp;author=KM+Scott&amp;volume=25&amp;publication_year=2007&amp;pages=2406-2413&amp;pmid=17557954&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Govindan1">16. <span class="element-citation">Govindan R, Kratzke RA, Herndon JE, 2nd, Niehans GA, Vollmer R, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. <span><span class="ref-journal">Clin Cancer Res. </span>2005;<span class="ref-vol">11</span>:2300–2304.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15788680" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Gefitinib+in+patients+with+malignant+mesothelioma:+a+phase+II+study+by+the+Cancer+and+Leukemia+Group+B.&amp;author=R+Govindan&amp;author=RA+Kratzke&amp;author=JE+Herndon&amp;author=GA+Niehans&amp;author=R+Vollmer&amp;volume=11&amp;publication_year=2005&amp;pages=2300-2304&amp;pmid=15788680&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Boswell1">17. <span class="element-citation">Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. <span><span class="ref-journal">Nucl Med Biol. </span>2007;<span class="ref-vol">34</span>:757–778.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2212602/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17921028" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucl+Med+Biol&amp;title=Development+of+radioimmunotherapeutic+and+diagnostic+antibodies:+an+inside-out+view.&amp;author=CA+Boswell&amp;author=MW+Brechbiel&amp;volume=34&amp;publication_year=2007&amp;pages=757-778&amp;pmid=17921028&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Sharkey1">18. <span class="element-citation">Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. <span><span class="ref-journal">J Nucl Med. </span>2005;<span class="ref-vol">46</span>(Suppl 1):115S–127S.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15653660" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=Perspectives+on+cancer+therapy+with+radiolabeled+monoclonal+antibodies.&amp;author=RM+Sharkey&amp;author=DM+Goldenberg&amp;volume=46&amp;issue=Suppl+1&amp;publication_year=2005&amp;pages=115S-127S&amp;pmid=15653660&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Zinzani1">19. <span class="element-citation">Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:3998–4004.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20542986" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Phase+II+trial+of+short-course+R-CHOP+followed+by+90Y-ibritumomab+tiuxetan+in+previously+untreated+high-risk+elderly+diffuse+large+B-cell+lymphoma+patients.&amp;author=PL+Zinzani&amp;author=G+Rossi&amp;author=S+Franceschetti&amp;author=B+Botto&amp;author=A+Di+Rocco&amp;volume=16&amp;publication_year=2010&amp;pages=3998-4004&amp;pmid=20542986&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Richman1">20. <span class="element-citation">Richman CM, DeNardo SJ. Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. <span><span class="ref-journal">Crit Rev Oncol Hematol. </span>2001;<span class="ref-vol">38</span>:25–35.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11255079" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Crit+Rev+Oncol+Hematol&amp;title=Systemic+radiotherapy+in+metastatic+breast+cancer+using+90Y-linked+monoclonal+MUC-1+antibodies.&amp;author=CM+Richman&amp;author=SJ+DeNardo&amp;volume=38&amp;publication_year=2001&amp;pages=25-35&amp;pmid=11255079&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Wong1">21. <span class="element-citation">Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, et al. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. <span><span class="ref-journal">Cancer Biother Radiopharm. </span>2006;<span class="ref-vol">21</span>:88–100.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16706629" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Biother+Radiopharm&amp;title=A+phase+I+trial+of+(90)Y-DOTA-anti-CEA+chimeric+T84.66+(cT84.66)+radioimmunotherapy+in+patients+with+metastatic+CEA-producing+malignancies.&amp;author=JY+Wong&amp;author=DZ+Chu&amp;author=LE+Williams&amp;author=A+Liu&amp;author=J+Zhan&amp;volume=21&amp;publication_year=2006&amp;pages=88-100&amp;pmid=16706629&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Verel1">22. <span class="element-citation">Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. <span><span class="ref-journal">J Nucl Med. </span>2003;<span class="ref-vol">44</span>:1663–1670.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14530484" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=Quantitative+89Zr+immuno-PET+for+in+vivo+scouting+of+90Y-labeled+monoclonal+antibodies+in+xenograft-bearing+nude+mice.&amp;author=I+Verel&amp;author=GW+Visser&amp;author=R+Boellaard&amp;author=OC+Boerman&amp;author=J+van+Eerd&amp;volume=44&amp;publication_year=2003&amp;pages=1663-1670&amp;pmid=14530484&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Lovqvist1">23. <span class="element-citation">Lovqvist A, Humm JL, Sheikh A, Finn RD, Koziorowski J, et al. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. <span><span class="ref-journal">J Nucl Med. </span>2001;<span class="ref-vol">42</span>:1281–1287.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11483692" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=PET+imaging+of+(86)Y-labeled+anti-Lewis+Y+monoclonal+antibodies+in+a+nude+mouse+model:+comparison+between+(86)Y+and+(111)In+radiolabels.&amp;author=A+Lovqvist&amp;author=JL+Humm&amp;author=A+Sheikh&amp;author=RD+Finn&amp;author=J+Koziorowski&amp;volume=42&amp;publication_year=2001&amp;pages=1281-1287&amp;pmid=11483692&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Helisch1">24. <span class="element-citation">Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. <span><span class="ref-journal">Eur J Nucl Med Mol Imaging. </span>2004;<span class="ref-vol">31</span>:1386–1392.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15175836" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Nucl+Med+Mol+Imaging&amp;title=Pre-therapeutic+dosimetry+and+biodistribution+of+86Y-DOTA-Phe1-Tyr3-octreotide+versus+111In-pentetreotide+in+patients+with+advanced+neuroendocrine+tumours.&amp;author=A+Helisch&amp;author=GJ+Forster&amp;author=H+Reber&amp;author=HG+Buchholz&amp;author=R+Arnold&amp;volume=31&amp;publication_year=2004&amp;pages=1386-1392&amp;pmid=15175836&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Nayak1">25. <span class="element-citation">Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A''-DTPA-bevacizumab. <span><span class="ref-journal">Int J Cancer. </span>2011;<span class="ref-vol">128</span>:920–926.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2939172/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20473899" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=PET+imaging+of+tumor+angiogenesis+in+mice+with+VEGF-A-targeted+(86)Y-CHX-A''-DTPA-bevacizumab.&amp;author=TK+Nayak&amp;author=K+Garmestani&amp;author=KE+Baidoo&amp;author=DE+Milenic&amp;author=MW+Brechbiel&amp;volume=128&amp;publication_year=2011&amp;pages=920-926&amp;pmid=20473899&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Philpott1">26. <span class="element-citation">Philpott GW, Schwarz SW, Anderson CJ, Dehdashti F, Connett JM, et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. <span><span class="ref-journal">J Nucl Med. </span>1995;<span class="ref-vol">36</span>:1818–1824.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7562049" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=RadioimmunoPET:+detection+of+colorectal+carcinoma+with+positron-emitting+copper-64-labeled+monoclonal+antibody.&amp;author=GW+Philpott&amp;author=SW+Schwarz&amp;author=CJ+Anderson&amp;author=F+Dehdashti&amp;author=JM+Connett&amp;volume=36&amp;publication_year=1995&amp;pages=1818-1824&amp;pmid=7562049&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Cutler1">27. <span class="element-citation">Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. <span><span class="ref-journal">J Nucl Med. </span>1995;<span class="ref-vol">36</span>:2363–2371.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8523133" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=Dosimetry+of+copper-64-labeled+monoclonal+antibody+1A3+as+determined+by+PET+imaging+of+the+torso.&amp;author=PD+Cutler&amp;author=SW+Schwarz&amp;author=CJ+Anderson&amp;author=JM+Connett&amp;author=MJ+Welch&amp;volume=36&amp;publication_year=1995&amp;pages=2363-2371&amp;pmid=8523133&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Milenic1">28. <span class="element-citation">Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease. <span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>:1926–1935.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17363549" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Potentiation+of+high-LET+radiation+by+gemcitabine:+targeting+HER2+with+trastuzumab+to+treat+disseminated+peritoneal+disease.&amp;author=DE+Milenic&amp;author=K+Garmestani&amp;author=ED+Brady&amp;author=PS+Albert&amp;author=A+Abdulla&amp;volume=13&amp;publication_year=2007&amp;pages=1926-1935&amp;pmid=17363549&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Nayak2">29. <span class="element-citation">Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. <span><span class="ref-journal">J Nucl Med. </span><span class="ref-vol">51</span>:942–950.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2892806/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20484421" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=Preparation,+biological+evaluation,+and+pharmacokinetics+of+the+human+anti-HER1+monoclonal+antibody+panitumumab+labeled+with+86Y+for+quantitative+PET+of+carcinoma.&amp;author=TK+Nayak&amp;author=K+Garmestani&amp;author=KE+Baidoo&amp;author=DE+Milenic&amp;author=MW+Brechbiel&amp;volume=51&amp;pages=942-950&amp;pmid=20484421&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Nayak3">30. <span class="element-citation">Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, et al. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab. <span><span class="ref-journal">Eur J Nucl Med Mol Imaging. </span><span class="ref-vol">37</span>:1368–1376.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2891840/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20155263" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Nucl+Med+Mol+Imaging&amp;title=PET+imaging+of+HER1-expressing+xenografts+in+mice+with+86Y-CHX-A&#x02019;&#x02019;-DTPA-cetuximab.&amp;author=TK+Nayak&amp;author=CA+Regino&amp;author=KJ+Wong&amp;author=DE+Milenic&amp;author=K+Garmestani&amp;volume=37&amp;pages=1368-1376&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Behr1">31. <span class="element-citation">Behr TM, Behe M, Stabin MG, Wehrmann E, Apostolidis C, et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. <span><span class="ref-journal">Cancer Res. </span>1999;<span class="ref-vol">59</span>:2635–2643.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10363986" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=High-linear+energy+transfer+(LET)+alpha+versus+low-LET+beta+emitters+in+radioimmunotherapy+of+solid+tumors:+therapeutic+efficacy+and+dose-limiting+toxicity+of+213Bi-+versus+90Y-labeled+CO17-1A+Fab'+fragments+in+a+human+colonic+cancer+model.&amp;author=TM+Behr&amp;author=M+Behe&amp;author=MG+Stabin&amp;author=E+Wehrmann&amp;author=C+Apostolidis&amp;volume=59&amp;publication_year=1999&amp;pages=2635-2643&amp;pmid=10363986&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Heelan1">32. <span class="element-citation">Heelan RT, Rusch VW, Begg CB, Panicek DM, Caravelli JF, et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. <span><span class="ref-journal">AJR Am J Roentgenol. </span>1999;<span class="ref-vol">172</span>:1039–1047.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10587144" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AJR+Am+J+Roentgenol&amp;title=Staging+of+malignant+pleural+mesothelioma:+comparison+of+CT+and+MR+imaging.&amp;author=RT+Heelan&amp;author=VW+Rusch&amp;author=CB+Begg&amp;author=DM+Panicek&amp;author=JF+Caravelli&amp;volume=172&amp;publication_year=1999&amp;pages=1039-1047&amp;pmid=10587144&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Lee2">33. <span class="element-citation">Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, et al. Volume-Based Parameter of (18)F-FDG PET/CT in Malignant Pleural Mesothelioma Prediction of Therapeutic Response and Prognostic Implications. <span><span class="ref-journal">Ann Surg Oncol </span></span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20461469" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Surg+Oncol&amp;title=Volume-Based+Parameter+of+(18)F-FDG+PET/CT+in+Malignant+Pleural+Mesothelioma+Prediction+of+Therapeutic+Response+and+Prognostic+Implications.&amp;author=HY+Lee&amp;author=SH+Hyun&amp;author=KS+Lee&amp;author=BT+Kim&amp;author=J+Kim&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Nowak1">34. <span class="element-citation">Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:2409–2417.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20371686" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=A+novel+prognostic+model+for+malignant+mesothelioma+incorporating+quantitative+FDG-PET+imaging+with+clinical+parameters.&amp;author=AK+Nowak&amp;author=RJ+Francis&amp;author=MJ+Phillips&amp;author=MJ+Millward&amp;author=AA+van+der+Schaaf&amp;volume=16&amp;publication_year=2010&amp;pages=2409-2417&amp;pmid=20371686&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Benamore1">35. <span class="element-citation">Benamore RE, O'Doherty MJ, Entwisle JJ. Use of imaging in the management of malignant pleural mesothelioma. <span><span class="ref-journal">Clin Radiol. </span>2005;<span class="ref-vol">60</span>:1237–1247.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16291305" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Radiol&amp;title=Use+of+imaging+in+the+management+of+malignant+pleural+mesothelioma.&amp;author=RE+Benamore&amp;author=MJ+O'Doherty&amp;author=JJ+Entwisle&amp;volume=60&amp;publication_year=2005&amp;pages=1237-1247&amp;pmid=16291305&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Kramer1">36. <span class="element-citation">Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, et al. PET for the evaluation of pleural thickening observed on CT. <span><span class="ref-journal">J Nucl Med. </span>2004;<span class="ref-vol">45</span>:995–998.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15181135" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Nucl+Med&amp;title=PET+for+the+evaluation+of+pleural+thickening+observed+on+CT.&amp;author=H+Kramer&amp;author=RM+Pieterman&amp;author=DJ+Slebos&amp;author=W+Timens&amp;author=W+Vaalburg&amp;volume=45&amp;publication_year=2004&amp;pages=995-998&amp;pmid=15181135&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Tsao1">37. <span class="element-citation">Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:2081–2090.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC4881753/">PMC free article</a>]</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19255316" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Malignant+pleural+mesothelioma.&amp;author=AS+Tsao&amp;author=I+Wistuba&amp;author=JA+Roth&amp;author=HL+Kindler&amp;volume=27&amp;publication_year=2009&amp;pages=2081-2090&amp;pmid=19255316&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Lobo1">38. <span class="element-citation">Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. <span><span class="ref-journal">J Pharm Sci. </span>2004;<span class="ref-vol">93</span>:2645–2668.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15389672" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Pharm+Sci&amp;title=Antibody+pharmacokinetics+and+pharmacodynamics.&amp;author=ED+Lobo&amp;author=RJ+Hansen&amp;author=JP+Balthasar&amp;volume=93&amp;publication_year=2004&amp;pages=2645-2668&amp;pmid=15389672&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Wang1">39. <span class="element-citation">Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2008;<span class="ref-vol">84</span>:548–558.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18784655" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Pharmacol+Ther&amp;title=Monoclonal+antibody+pharmacokinetics+and+pharmacodynamics.&amp;author=W+Wang&amp;author=EQ+Wang&amp;author=JP+Balthasar&amp;volume=84&amp;publication_year=2008&amp;pages=548-558&amp;pmid=18784655&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Milenic2">40. <span class="element-citation">Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. <span><span class="ref-journal">Clin Cancer Res. </span>2004;<span class="ref-vol">10</span>:7834–7841.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15585615" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Targeting+of+HER2+antigen+for+the+treatment+of+disseminated+peritoneal+disease.&amp;author=DE+Milenic&amp;author=K+Garmestani&amp;author=ED+Brady&amp;author=PS+Albert&amp;author=D+Ma&amp;volume=10&amp;publication_year=2004&amp;pages=7834-7841&amp;pmid=15585615&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Garmestani1">41. <span class="element-citation">Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. <span><span class="ref-journal">Nucl Med Biol. </span>2002;<span class="ref-vol">29</span>:599–606.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12088731" ref="reftype=pubmed&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nucl+Med+Biol&amp;title=A+new+and+convenient+method+for+purification+of+86Y+using+a+Sr(II)+selective+resin+and+comparison+of+biodistribution+of+86Y+and+111In+labeled+Herceptin.&amp;author=K+Garmestani&amp;author=DE+Milenic&amp;author=PS+Plascjak&amp;author=MW+Brechbiel&amp;volume=29&amp;publication_year=2002&amp;pages=599-606&amp;pmid=12088731&amp;" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0018198-Gibaldi1">42. <span class="element-citation">Gibaldi M, Perrier D.  New York: Dekker; 1982. Pharmacokinetics. p. viii, 494. <span class="nowrap">[<a href="https://scholar.google.com/scholar?q=Gibaldi+M+Perrier+D+1982+Pharmacokinetics.+New+York+Dekker+viii,+494+" target="_blank" rel="noopener noreferrer" ref="reftype=other&amp;article-id=3064677&amp;issue-id=194635&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr /><div class="half_rhythm">Articles from <span class="acknowledgment-journal-title">PLOS ONE</span> are provided here courtesy of <strong>PLOS</strong></div><hr /></div><div id="body-link-poppers"><span></span></div></div>
            
        </section>
    </article>
    <aside class="usa-width-one-fourth usa-layout-docs-sidenav pmc-sidebar">
         
  

<div class="scroller">

    
        <section>
                <h6>Other Formats</h6>
                <ul class="pmc-sidebar__formats">
                  <li class="pdf-link other_item"><a href="/pmc/articles/PMC3064677/pdf/pone.0018198.pdf" class="int-view">PDF (1.3M)</a></li>
                </ul>
        </section>
    
    <section>
        <h6>Actions</h6>
        <ul class="pmc-sidebar__actions">
            <li>
                <button role="button" class="citation-button citation-dialog-trigger ctxp"
                        aria-label="Open dialog with citation text in different styles" data-ga-category="save_share" data-ga-action="cite" data-ga-label="open"
                        data-all-citations-url="/pmc/resources/citations/3064677/"
                        data-citation-style="nlm"
                        data-download-format-link="/pmc/resources/citations/3064677/export/"
                >
                    <span class="button-label">Cite</span>
                </button>
            </li>
            <li>
                
                    

<link type="text/css" href="ncbi-overlay-block/src/overlay-block.css">
<div class="collections-button-container" data-article-id="3064677" data-article-db="pmc">
  <button class="collections-button collections-dialog-trigger"
          aria-label="Save article in MyNCBI collections."
          data-ga-category="collections_button"
          data-ga-action="click"
          data-ga-label="collections_button"
          data-collections-open-dialog-enabled="false"
          data-collections-open-dialog-url="https://www.ncbi.nlm.nih.gov/account?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F%23open-collections-dialog"
          data-in-collections="false">
      <span class="button-label">Collections</span>
  </button>
  <div class="overlay" role="dialog">
  <div id="collections-action-dialog"
       class="dialog collections-dialog"
       aria-hidden="true">
    <div class="title">Add to Collections</div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/pmc/list-existing-collections/"
      data-add-to-existing-collection-url="/pmc/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/pmc/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

  <input type="hidden" name="csrfmiddlewaretoken" value="kKxztmzvrziR0as7FBAJPdB0Gt4Kg5G4p6vVAryEaCouXy5CAWN8Se6IHA7H9qmn">

  

  <div class="choice-group" role="radiogroup">
    <ul class="radio-group-items">
      <li>
        <input type="radio"
               id="collections-action-dialog-new-aside "
               class="collections-new"
               name="collections"
               value="new"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_new">
        <label for="collections-action-dialog-new-aside ">Create a new collection</label>
      </li>
      <li>
        <input type="radio"
               id="collections-action-dialog-existing-aside "
               class="collections-existing"
               name="collections"
               value="existing"
               checked="true"
               data-ga-category="collections_button"
               data-ga-action="click"
               data-ga-label="collections_radio_existing">
        <label for="collections-action-dialog-existing-aside ">Add to an existing collection</label>
      </li>
    </ul>
  </div>

  <div class="controls-wrapper">
    <div class="action-panel-control-wrap new-collections-controls">
      <label for="collections-action-dialog-add-to-new" class="action-panel-label required-field-asterisk">
        Name your collection:
      </label>
      <input
        type="text"
        name="add-to-new-collection"
        id="collections-action-dialog-add-to-new"
        class="collections-action-add-to-new"
        pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
        maxlength=""
        data-ga-category="collections_button"
        data-ga-action="create_collection"
        data-ga-label="non_favorties_collection">
      <div class="collections-new-name-too-long usa-input-error-message selection-validation-message">
        Name must be less than  characters
      </div>
    </div>
    <div class="action-panel-control-wrap existing-collections-controls">
      <label for="collections-action-dialog-add-to-existing" class="action-panel-label">
        Choose a collection:
      </label>
      <select id="collections-action-dialog-add-to-existing"
              class="action-panel-selector collections-action-add-to-existing"
              data-ga-category="collections_button"
              data-ga-action="select_collection"
              data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
      </select>
      <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
        Unable to load your collection due to an error<br>
        <a href="#">Please try again</a>
      </div>
    </div>
  </div>

  <div class="action-panel-actions">
    <button class="action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
      Add
    </button>
    <button class="action-panel-cancel"
            aria-label="Close 'Add to Collections' panel"
            ref="linksrc=close_collections_panel"
            aria-controls="collections-action-panel"
            aria-expanded="false"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="cancel">
      Cancel
    </button>
  </div>
</form>
    </div>
  </div>
</div>
</div>
                
            </li>

        </ul>
    </section>
    
        <section class="social-sharing">
            <h6>Share</h6>
            <ul class="pmc-sidebar__share">
                <li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F&amp;text=HER1-Targeted%2086Y-Panitumumab%20Possesses%20Superior%20Targeting%20Characteristics%20than%2086Y-Cetuximab%20for%20PET%20Imaging%20of%20..." alt="Share on Twitter"><i class="fa fa-twitter fa-stack-1x">&#160;</i></a></li> 
<li><a class="fa-stack fa-lg" target="_blank" rel="noopener noreferrer" role="button" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3064677%2F" alt="Share on Facebook"><i class="fa fa-facebook fa-stack-1x">&#160;</i></a></li>
                <li>
                    <div class="share-permalink">
                        <button class="trigger"  alt="Show article permalink" aria-expanded="false" aria-haspopup="true">
                            <i class="fa-stack fa-lg" >
                                <i class="fa fa-link fa-stack-1x">&nbsp;</i>
                            </i>
                        </button>
                        <div class="dropdown dropdown-container" hidden>
                              <div class="title">
                                Permalink
                              </div>
                              <div class="content">
                                  <input type="text" class="permalink-text" value="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064677/" aria-label="Article permalink"><button class="permalink-copy-button usa-button-primary" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                                      <span class="button-title">Copy</span>
                                  </button>
                              </div>
                        </div>
                    </div>
                </li>
            </ul>
        </section>
    
    <section>
        <h6>RESOURCES</h6>
        <ul class="pmc-sidebar__resources">
        
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_similar_articles"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="similar-articles-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_similar_articles"
                            data-action-close="close_similar_articles"
                    >
                        Similar articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/similar-article-links/21464917/"
                            

                         class="usa-accordion-content pmc-sidebar__resources--citations" id="similar-articles-accordion-aside" aria-hidden="true">
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_cited_by"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="cited-by-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_cited_by"
                            data-action-close="close_cited_by"
                    >
                        Cited by other articles
                    </button>
                    <div
                            
                                data-source-url="/pmc/resources/cited-by-links/21464917/"
                            
                            class="usa-accordion-content pmc-sidebar__resources--citations"
                            id="cited-by-accordion-aside"
                            aria-hidden="true"
                    >
                        
                    </div>
                </div>
            </li>
            <li>
                <div class="usa-accordion">
                    <button
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/pmc/articles/PMC3064677/"
                            class="usa-accordion-button"
                            aria-controls="links-accordion-aside"
                            aria-expanded="false"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                    >
                        Links to NCBI Databases
                    </button>
                    <div data-source-url="/pmc/resources/db-links/3064677/" class="usa-accordion-content" id="links-accordion-aside" aria-hidden="true"></div>
                </div>
            </li>

            
        
        </ul>
    </section>

 </div>

    </aside>
</main>

    <div class="overlay" role="dialog" aria-label="Citation Dialog">
  <div class="dialog citation-dialog">
    <button class="close-overlay" tabindex="1">[x]</button>
    <div class="title">Cite</div>
    <div class="citation-text-block">
  <div class="citation-text"></div>
  <div class="citation-actions">
    <button
      class="copy-button dialog-focus"
      data-ga-category="save_share"
      data-ga-action="cite"
      data-ga-label="copy"
      tabindex="2">
      Copy
    </button>

      <a href="#"
              class="export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
          <span class="title">Download .nbib</span>
          <span class="title-mobile">.nbib</span>
      </a>


    

<div class="citation-style-selector-wrapper">
  <label class="selector-label">Format:</label>
  <select aria-label="Format" class="citation-style-selector" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
  </div>
</div>
  </div>
</div>

     <!-- ========== BEGIN FOOTER ========== -->
 <footer>
      <section class="icon-section">
        <div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
        <div class="grid-container container">
          <div class="icon-section_container">
            <a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11 {
                      fill: #737373;
                    }
                  </style>
                </defs>
                <title>Twitter</title>
                <path class="cls-11"
                  d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>Facebook</title>
                <path class="cls-11"
                  d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_linkedin"
              href="https://www.linkedin.com/company/ncbinlm"
              aria-label="LinkedIn"><svg data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <title>LinkedIn</title>
                <path class="cls-11"
                  d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
                </path>
              </svg></a>
            <a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg
                data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 300 300">
                <defs>
                  <style>
                    .cls-11,
                    .cls-12 {
                      fill: #737373;
                    }

                    .cls-11 {
                      fill-rule: evenodd;
                    }
                  </style>
                </defs>
                <title>GitHub</title>
                <path class="cls-11"
                  d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
                </path>
                <path class="cls-12"
                  d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
                </path>
                <path class="cls-12"
                  d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
                </path>
                <path class="cls-12"
                  d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
                <path class="cls-12"
                  d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
                </path>
                <path class="cls-12"
                  d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
                </path>
                <path class="cls-12"
                  d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
                </path>
                <path class="cls-12"
                  d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
              </svg></a>
            <a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
              <svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 40"><defs><style>.cls-1{fill:#737373;}</style></defs><path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"/></svg>
            </a>
          </div>
        </div>
      </section>

      <section class="container-fluid bg-primary">
        <div class="container pt-5">
          <div class="row mt-3">
            <div class="col-lg-3 col-12">
              <p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
              <ul class="list-inline social_media">
                <li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st20 {
                          fill: #FFFFFF;
                        }

                        .st30 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Twitter</title>
                      <g>
                        <g>
                          <g>
                            <path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7
                                                c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116
                                                c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3
                                                c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6
                                                C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
                          </g>
                        </g>
                        <circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
                      </g>
                    </svg></a></li>
                <li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine"
                    aria-label="Facebook" rel="noopener noreferrer" target="_blank">
                    <svg version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px"
                      y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <style type="text/css">
                        .st10 {
                          fill: #FFFFFF;
                        }

                        .st110 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }
                      </style>
                      <title>SM-Facebook</title>
                      <g>
                        <g>
                          <path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9
                                                      v67.5H135v-67.5h21.7L159,99.1z"></path>
                        </g>
                      </g>
                      <circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
                    </svg>
                  </a></li>
                <li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube"
                    target="_blank" rel="noopener noreferrer"><svg version="1.1" xmlns="http://www.w3.org/2000/svg"
                      xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 249 249"
                      style="enable-background:new 0 0 249 249;" xml:space="preserve">
                      <title>SM-Youtube</title>
                      <style type="text/css">
                        .st4 {
                          fill: none;
                          stroke: #FFFFFF;
                          stroke-width: 8;
                          stroke-miterlimit: 10;
                        }

                        .st5 {
                          fill: #FFFFFF;
                        }
                      </style>
                      <circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
                      <g transform="translate(0,-952.36218)">
                        <path class="st5"
                          d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7
                                            v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
                      </g>
                    </svg></a></li>
              </ul>
            </div>
            <div class="col-lg-3 col-12">
              <p class="address_footer text-white">National Library of Medicine<br>
                <a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323"
                  class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br>
                  Bethesda, MD 20894</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br>
                <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office"
                  class="text-white">FOIA</a><br>
                <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
            </div>
            <div class="col-lg-3 col-12 centered-lg">
              <p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br>
                <a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br>
                <a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
            </div>
          </div>
          <div class="row">
            <div class="col-lg-12 centered-lg">
              <nav class="bottom-links">
                <ul class="mt-3">
                  <li>
                    <a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
                  </li>
                  <li>
                    <a class="text-white"
                  href="https://www.nih.gov/">NIH</a>
                  </li>
                  <li>
                    <a class="text-white" href="https://www.hhs.gov/">HHS</a>
                  </li>
                  <li>
                    <a
                  class="text-white" href="https://www.usa.gov/">USA.gov</a>
                  </li>
                </ul>
              </nav>
            </div>
          </div>
        </div>
      </section>
    </footer>
 <!-- ========== END FOOTER ========== -->
  <!-- javascript to inject NWDS meta tags. Note: value of nwds_version is updated by "npm version" command -->
 
  <script type="text/javascript">
    var nwds_version = "1.1.9-2";

    var meta_nwds_ver = document.createElement('meta');
    meta_nwds_ver.name = 'ncbi_nwds_ver';
    meta_nwds_ver.content = nwds_version;
    document.getElementsByTagName('head')[0].appendChild(meta_nwds_ver);

    var meta_nwds = document.createElement('meta');
    meta_nwds.name = 'ncbi_nwds';
    meta_nwds.content = 'yes';
    document.getElementsByTagName('head')[0].appendChild(meta_nwds);

	var alertsUrl = "/core/alerts/alerts.js";
	if (typeof ncbiBaseUrl !== 'undefined') {
		alertsUrl = ncbiBaseUrl + alertsUrl;
	}
  </script>



  
    <!-- JavaScript -->
    <script src="/pmc/static/CACHE/js/output.0f72d6a64937.js"></script>
  
  
    <script src="https://code.jquery.com/jquery-3.5.0.min.js"
          integrity="sha256-xNzN2a4ltkB44Mc/Jz3pT4iU1cmeR0FkXs4pru/JxaQ="
          crossorigin="anonymous">
    </script>
    <script>
        var fallbackJquery = "/pmc/static/base/js/jquery-3.5.0.min.js";
        window.jQuery || document.write("<script src=" + fallbackJquery + ">\x3C/script>")
    </script>
  

  <script src="/pmc/static/CACHE/js/output.a212a9fcf845.js"></script>
<script src="/pmc/static/CACHE/js/output.7999321d1aac.js"></script>
<script src="/pmc/static/CACHE/js/output.7ca436b2ea51.js"></script>
<script src="/pmc/static/CACHE/js/output.f8422046fbe0.js"></script>
<script src="/pmc/static/CACHE/js/output.ff40c7d85ff8.js"></script>
<script src="/pmc/static/CACHE/js/output.a6a84a0ad361.js"></script>

<script type="text/javascript" src="/pmc/static/bundles/base/base.038d36e4e31104b40a19.js" ></script>

    <script type="text/javascript">
        if(typeof jQuery !=='undefined') {
            jQuery.migrateMute = true;
        }
    </script>
    <script type="text/javascript" src="https://code.jquery.com/jquery-migrate-1.4.1.js"></script>
    <script type="text/javascript" src="/core/jig/1.15.2/js/jig.nojquery.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/crb.min.js?_=3.18">//</script><script type="text/javascript" src="/corehtml/pmc/js/jactions.min.js?_=3.18">//</script><script type="text/javascript">window.name="mainwindow";</script>

    <script type="text/javascript">var exports = {};</script>
    <script src="/pmc/static/CACHE/js/output.340a3b9cce7f.js"></script>
<script src="/pmc/static/CACHE/js/output.228f96f3298e.js"></script>
    <script type="text/javascript" src="/pmc/static/bundles/article/article.b7dd20e527283dd68f45.js" ></script>
    <script type="text/javascript">
        window.ncbi.pmc.articlePage.init({ pageURL: '/pmc/articles/PMC3064677/', citeCookieName: 'pmc-cf'});
    </script>


  
  
  <script  type="text/javascript" src="https://www.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


  
      
  

</body>
</html>
